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Abstract
How different is the immune system in a human from that of a mouse? Do pathogens
replicate at the same rate in different species? Answers to these questions have impact on human health since multi-host pathogens that jump from animals to humans
affect millions worldwide.
It is not known how rates of immune response and viral dynamics vary from
species to species and how they depend on species body size. Metabolic scaling
theory predicts that intracellular processes will be slower in larger animals since
cellular metabolic rates are slower. We test how rates of pathogenesis and immune
system response rates depend on species body size.
We hypothesize that immune response rates are invariant with body size. Our
work suggests how the physical architecture of the immune system and chemical
signals within it may lead to nearly scale-invariant immune search and response.
We fit mathematical models to experimental West Nile Virus (WNV, a multi-host
pathogen) infection data and investigate how model parameters characterizing the
pathogen and the immune response change with respect to animal mass.

vi

Phylogeny also affects pathogenesis and immune response. We use a hierarchical
Bayesian model, that incorporates phylogeny, to test hypotheses about the role of
mass and phylogeny on pathogen replication and immune response. We observe that:
1. Hierarchical models (informed by phylogeny) make more accurate predictions
of experimental data and more realistic estimates of biologically relevant parameters characterizing WNV infection.
2. Rates of WNV production decline with species body mass, modified by a phylogenetic influence.
Our work is the first to systematically explore the role of host body mass in
pathogenesis using mathematical models and empirical data. We investigate the
complex interplay between the physical structure of the immune system and host
body mass in determining immune response. The modeling strategies and tools
outlined here are likely to be applicable to modeling of other multi-host pathogens.
This work could also be extended to understand how drug and vaccine efficacy in
humans may systematically differ from that in model organisms like mice, in which
most initial experimental studies are conducted.
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Chapter 1
Introduction

Many emerging pathogens infect multiple host species [8], and multi-host pathogens
may have very different dynamics in different species [9]. Zoonotic diseases that jump
the species barrier from animals to humans cause 2.5 billion cases of human illness
and 2.7 million human deaths per year [10]. Many emerging diseases are zoonotic in
origin.
Understanding how quickly pathogens replicate and how quickly the immune system responds is important for predicting the epidemic spread of emerging pathogens,
many of which are zoonotic. While host pathogen interactions have been studied
qualitatively using mathematical models, it is not known how the parameters characterizing the immune response and pathogen replication rates change from species
to species. Emerging zoonotic diseases originate from species that differ in body size,
e.g. birds in avian influenza and cattle in BSE (Bovine Spongiform Encephalopathy). Thus it is important to understand how body size affects immune response and
pathogenesis.
Body size can affect pathogenesis in two ways:
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1. Host metabolism constrains energy delivery to cells [11, 12] and could influence
rates of pathogen replication and immune response rates [6]. The metabolic
rate of each cell is constrained by the rate at which nutrients and oxygen
are supplied by the cardio-vascular network. The rate at which this network
supplies nutrients to each cell (Rcell ) scales as the body mass (M ) raised to an
exponent of -1/4: Rcell ∝ M −1/4 such that individual cellular metabolic rates
decrease as the body mass increases [11, 12]. This relationship holds over an
incredible diversity of body sizes, from 10−13 g (microbes) to 108 g (whales).
Many biological rates, such as heart rates and reproductive rates, scale as
M −1/4 , while many times such as blood circulation times and life times, scale
as M 1/4 (times) [11].
Cellular metabolic rate dictates the pace of many biological processes [12].
Cellular metabolism could affect immune system search times by reducing
movement and proliferation of immune cells [6]. Rates of DNA and protein
synthesis also depend on the cellular metabolic rate and could influence the
rate at which pathogens replicate inside infected cells [9]. Using mathematical
models and experimental data, we test whether viral replication and immune
response varies with species mass. We use West Nile Virus (WNV) as a model
pathogen for our studies because it is a generalist pathogen that infects many
species in different taxonomic groups and with a range of body sizes.
2. An effective immune response requires efficient detection of pathogens that may
be initially localized. The detection of small amounts of pathogen is harder in
larger animals due to larger physical spaces. We hypothesize that the immune
system is capable of nearly scale-invariant detection and response, i.e. rates
of immune response and time taken by the immune system to detect and respond to pathogens do not scale appreciably with host body size. We suggest
how: a) the physical architecture of the immune system, comprised of anatomical structures called lymph nodes (that faciliate recognition of pathogen by
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immune system cells), and b) chemical signalling within the immune system,
guiding immune system cells to sites of infection, enable efficient and nearly
scale-invariant detection and response.
WNV pathogenesis also depends on phylogeny, e.g. Passerine species sustain
more viremia than non-Passerine species [5]. Hence phylogeny is expected to affect
immune response and pathogen replication rates. Viral dynamics may be similar in
related species. Modeling techniques that take advantage of relatedness of infected
species may produce more accurate results. We aim to incorporate phylogenetic
hierarchy to make better estimates of biologically relevant quantities for WNV.
Hierarchical Bayesian models enable modelers to encapsulate knowledge about
the underlying biology as priors. Hierarchical models also pool information across
disparate individuals from different groups and are well suited for cases where there
are a limited number of observations from several individuals. Suitable priors in
a hierarchical Bayesian framework can help reduce variance of parameter estimates
[13]. A model that incorporates the hierarchal nature of phylogeny and encodes this
information as priors in a hierarchical Bayesian model may enable more accurate
estimates of parameters characterizing WNV infection.
Hierarchical Bayesian models have been used in image processing [14], ecological
modeling [15] and climate modeling [16]. Bayesian non-linear mixed effects models
with a single level of hierarchy have been applied to modeling of the within-host
response to HIV [17, 18] and influenza [19]. Multilevel data fitting approaches and
Bayesian frameworks are expected to be helpful to modeling within-host viral dynamics [20]. However to the best of our knowledge, Bayesian non-linear mixed effects
models with multiple levels of hierarchy have not been applied to within-host modeling. Mathematical models that combine within-host experimental data from multiple
species, such as the ones presented here, may also be useful in studying other zoonotic
diseases and help increase our understanding of these diseases.
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Our goals are:

1. to test how the physical architecture of the immune system and chemical signals
within it affect immune response times. This is investigated in Chapters 3
and 4.
2. to characterize dynamics of WNV in mice using ordinary differential equation
models. This is explored in Chapter 5.
3. to test if a hierarchical Bayesian model that incorporates phylogeny allows
more refined predictions. This is explored in Chapter 6.
4. to apply the hierarchical Bayesian model to test the effect of species mass and
phylogeny on rates of pathogen replication and immune response in WNV. This
is investigated in Chapter 7.

1.1

Background on West Nile Virus

We use WNV as a model pathogen for our studies because it is a generalist pathogen
that infects many species in different taxonomic groups and with a range of body
sizes. WNV is a neurotropic flavivirus that has emerged globally as a significant cause
of viral encephalitis. WNV is maintained in an enzootic cycle between mosquitoes
and birds [21] but can also infect and cause disease in many other vertebrates including humans. Following its introduction into the United States in 1999, WNV spread
rapidly across the North American continent in only four years and more recently has
been reported in Mexico, South America, and the Caribbean [22, 23, 24]. Although
vaccines are available for animal use, no vaccines or specific therapies for WNV are
currently approved for humans [25].
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WNV is an enveloped virus with a single-stranded, positive sense, 11-kb RNA
genome [25]. WNV is cytopathic and initially infects epidermal Langerhans cells,
which then migrate to the draining lymph node and infect macrophages [25]. From
the draining lymph node, WNV spreads to the spleen, kidney, and spinal cord and
ultimately breaches the blood-brain barrier to infect neurons [25]. The standard
pattern of WNV infection in mice is characterized by an initial exponential growth of
virus that peaks around 3 to 4 days post infection (DPI), followed by an exponential
decline until that leads to undetectable levels of virus by 6 to 8 DPI.
WNV infects a large number of species across different taxonomic groups. This
allows us to test the effects of animal body size on pathogen replication and immune
response. We focus on data from a study which experimentally infected birds with
the same strain of WNV (WNV NY99-6480). The species infected range from 3
gm sparrows to 3 kg geese. Komar et al [5] experimentally infected 25 species of
birds with WNV NY99-6480 and took daily measurements of the concentration of
infective virions in blood (viremia) over the course of infection. Viremia was reported
in plaque forming units (PFU, a measure of the number of infectious virions) over a
span of at most 7 days post infection.
The order Passeriforme includes more than half of all bird species. The experimental infection study infected 10 Passerine species and 15 non-Passerine species.
The Passerine species were house finches, house sparrows, red winged blackbirds,
blue jays, American robins, European starlings, common grackles, black-billed magpies, fish crows and American crows. WNV is exceptionally viremic in corvid species
(a family within the order Passeriforme). The corvid species in the study were blue
jays, black-billed magpies, fish crows and American crows. The number of individuals
infected per species ranged from 1 (American coots) to 8 (American crows).
The experimental infection study included data on 87 individual birds belonging
to 25 distinct species. Of the 87 individuals infected, 26 succumbed to infection.
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With the exception of one individual (a non-Passerine ring billed gull), all mortality
was in Passerine species, primarily corvids.

1.2

Contributions and Organization

The remainder of the dissertation is divided into 7 chapters. The contributions of
these chapters are summarized below:
Chapter 2. This chapter outlines our computational approach, the unique computational challenges in this work and our solutions.
Chapter 3. An effective immune response requires efficient detection of pathogens
that may be initially localized. The detection of pathogens and response against
them is hypothesized to be more challenging in larger animals because the
search occurs in a larger physical space. We hypothesize that immune response
rates and times do not scale appreciably with host body size. This work suggests how the physical architecture of the immune system may lead to nearly
scale-invariant immune search and response. It also proposes an architecture
for an engineered distributed system (a multi-robot control system) that is inspired by the physical architecture of the immune system [26]. This chapter
was published by Soumya Banerjee and Melanie Moses in Swarm Intelligence
in 2010 [26].
Chapter 4. Rapid search is crucial for an effective immune response: Immune
system cells must find, identify and neutralize pathogens before those pathogens
replicate in sufficient numbers to cause disease or death. The adaptive immune
system has a small number of pathogen-specific cells that must search for and
neutralize initially localized pathogens in a very large tissue space. The immune
system uses information signals to accomplish this search quickly. This work
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suggests how chemical signals in the immune system accelerate this search. We
show that search times are reduced by over an order of magnitude in mice and
over two orders of magnitude in humans, suggesting that these signals play
an important role in the immune response, especially in larger animals [27].
This chapter was published by Soumya Banerjee, Drew Levin, Melanie Moses,
Frederick Koster and Stephanie Forrest in the 10th International Conference
on Artificial Immune Systems in 2011 [27].
Chapter 5. The qualitative dynamics of WNV have been best studied experimentally in mice. This chapter describes a method to predict biologically relevant
quantities for WNV infection in mice with the intention of gaining a quantitative understanding of WNV dynamics. Our novelty lies in uniquely combining
experimental data from knockout and wildtype mice using a succession of increasingly complex models. Despite large uncertainty in imposed bounds on
model parameters, our analysis yields tight estimates of a variety of biologically
relevant quantities that characterize WNV infection in mice [28]. Our method
could be more broadly applicable to modeling of other emerging pathogens with
large parameter uncertainty. This chapter was co-authored by Jeremie Guedj,
Ruy Ribeiro, Melanie Moses and Alan S. Perelson and is being prepared for
submission [28].
Chapter 6. As a first step towards developing a model of WNV dynamics in different species, this chapter develops a novel multi-level hierarchical Bayesian
model that incorporates phylogeny. In order to control the effect of noisy data
and model uncertainty, this chapter uses a known simple model to generate
simulated viremia data with varying amounts of noise. We then infer differential equation model parameters using the hierarchical model. The accuracy of
the hierarchical model is calculated by comparing the inferred parameter estimates to the actual parameter values (ground truth from known data). We find
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that our multi-level model (with prior information about differences between
species) can generate more accurate estimates under some circumstances.
Chapter 7. This chapter extends the multi-level hierarchical model from Chapter
6 by introducing a more realistic mathematical model of viral dynamics and
applying it to actual experimental data. We find that the multi-level model
produces more accurate predictions of viremia and more realistic estimates
of parameters. It also uncovers systematic differences in biologically relevant
parameters with species mass and phylogeny.
Chapter 8. This chapter concludes the dissertation by outlining the scaling relationships for rates of pathogen replication and the scale-invariance of immune
response rates and times. It also discusses implications for spread of zoonotic
diseases and design of human-engineered distributed systems. The chapter also
points out promising avenues for future investigations.
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Chapter 2
Computational Approach

We apply tools and approaches from complex systems and computer science to study
the immune system. An immune response is characterized by non-linear and dynamic interactions between the pathogen and the host immune system. We use both
spatially-explicit agent based models (ABM) and computationally tractable ordinary differential equation (ODE) models for simulating the immune system. In this
chapter, we outline all the computational techniques used, challenges faced and the
mathematical and engineering solutions we used to address those challenges.

2.1

Agent-Based Models

Chapter 3 uses the CyCells [29, 30] ABM platform to simulate the dynamics of trafficking of WNV to the lymph node. The CyCells [29, 30] modeling tool explicitly
represents healthy cells, infected cells, and immune system cells, and represents various chemicals released by the immune system as concentrations. The simulation is
conducted in a 3-dimensional cubic compartment.

9

Chapter 2. Computational Approach

2.2

Differential Equation Models

Chapters 5 to 7 use ODEs to simulate replication of WNV and the host immune
response to WNV. ODE models ignore space by assuming that all components are
well-mixed but have the advantage of being computationally tractable. The ODEs
describing our viral kinetic models were solved numerically using programs written
in Matlab [31] and Berkeley Madonna [32]. We used the Runge-Kutta 4 method of
integration. The curve-fitting method implemented in Matlab and also available in
Berkeley Madonna uses nonlinear least-squares regression that minimizes the sum of
the squared residuals between experimental data and ODE model predicted values.
We use two different ODE models to represent dynamics of WNV replication and
host immune response:

1. Target cell limited model. The target cell limited model assumes that the
concentration of virus reaches a peak and then declines when few susceptible
target cells remain. This model is represented by Eqs. 5.1 - 5.4.
2. Adaptive immune response model. The adaptive immune response model assumes that an adaptive antibody response causes the decline of virus concentration after a peak. This model is represented by Eqs. 5.7 - 5.11.

2.3

Hierarchical Bayesian models and Markov
Chain Monte Carlo

We use hierarchical Bayesian models to delineate the contribution of species mass and
phylogeny to WNV replication and the response of the host to WNV. We use Markov
chain Monte Carlo (MCMC) to draw samples from the distributions characterizing
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our ODE model parameters since they do not have an analytic closed-form.
The Bayesian inference approach can be described as follows. Assume that a
model (in our case a differential equation model describing how virus concentration
changes over time in serum) is represented by parameters Θ. The Bayesian approach
allows us to include prior knowledge about model parameters in a systematic fashion.
If we have information about Θ (for e.g., from experimental evidence) which needs to
be incorporated in our analysis, this is represented as a prior probability distribution
P (Θ). Bayes Rule allows us to incorporate the prior knowledge about parameters,
P (Θ), and experimental data, D, to derive a posterior distribution of parameters:

P (Θ|D) =

P (D|Θ) · P (Θ)
P (D)

(2.1)

The normalizing constant is chosen such that the posterior distribution, P (Θ|D),
R
integrates to 1, i.e. P (D) = P (D|Θ)·P (Θ)dΘ. We then use MCMC to numerically
integrate the terms in Eq. 2.1.

2.3.1

Metropolis-Hastings Sampler

We use two popular MCMC algorithms known as the Metropolis-Hastings sampler
and the Gibbs sampler. We use these algorithms to sample from the posterior distribution P (Θ|D). Let Θ(t) represent the state of the Markov chain at iteration
t of the algorithm. The Metropolis-Hastings sampler uses a proposal distribution
q(Θ|Θ(t−1) ) to generate a candidate point, Θ∗ , that is conditioned on the previous
state of the sampler, Θ(t−1) . In the next step, the algorithm either accepts or rejects
the candidate point based on an acceptance probability:
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α = min(1,

q(Θ(t−1) |Θ∗ )
P (Θ∗ )
·
)
P (Θ(t−1) ) q(Θ∗ |Θ(t−1) )

(2.2)

The Metropolis-Hastings algorithm is as follows:
1. Set t = 1
2. Generate an initial value u, and set Θ(t) = u
3. Repeat
t=t+1
Generate a candidate Θ∗ from the proposal distribution q(Θ|Θ(t−1) )
∗

P (Θ )
Evaluate the probability of acceptance, α = min(1, P (Θ
(t−1) ) ·

q(Θ(t−1) |Θ∗ )
)
q(Θ∗ |Θ(t−1) )

Generate a x from a Uniform(0,1) distribution
If x ≤ α, accept the candidate solution and set Θt = Θ∗ , else set Θt = Θ(t−1)
4. Until t = required number of iterations
The Metropolis-Hastings sampler has the advantage of not requiring knowledge
of the normalizing constant, P (D). In our case the parameter Θ is multi-variate
and has different components corresponding to the different ODE model parameters.
We accept or reject the candidate solution involving all components as a block simultaneously. This is known as a block-wise updating scheme. A component-wise
updating scheme updates each component in turn and independently of each other.

2.3.2

Gibbs Sampler

The Gibbs sampler is an algorithm in which all samples are accepted and hence
is computationally more efficient than the Metropolis-Hastings sampler. However,
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the Gibbs sampler can only be applied in the case when we know the full conditional distribution of each component of the parameter Θ conditioned on all other
components.
As an illustrative example, we show the workings of the Gibbs sampler for the
joint two-component distribution g(θ1 , θ2 ). The Gibbs sampler can be used if we can
derive the distribution of each component conditioned on the other, i.e. in this case
(t)

(t)

the conditional distributions g(θ1 |θ2 = θ2 ) and g(θ2 |θ1 = θ1 ). The Gibbs sampler
for the case of two-components is as follows:

1. Set t = 1
2. Generate an initial value u = (u1 , u2 ), and set Θ(t) = u
3. Repeat
t=t+1
(t)

(t−1)

(t)

(t)

Sample θ1 from the conditional distribution g(θ1 |θ2 = θ2

)

Sample θ2 from the conditional distribution g(θ2 |θ1 = θ1 )
4. Until t = required number of iterations

We update each component sequentially in turn (systematic-scan Gibbs sampler).
Our approach is to use the Metropolis-Hastings sampler within the Gibbs sampler; this involves using the computationally efficient Gibbs update steps whenever
the full posterior conditional distributions are known and using Metropolis-Hastings
acceptance steps when the full conditional distribution is not available.
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2.4

Bayesian Model Assumptions

The parameters in our ODE models vary over large ranges (frequently over many
orders of magnitude). Hence in order to stabilize the variance and also ensure that
estimates are positive, we assumed that all ODE model parameters characterizing
viral replication and immune response are lognormally distributed.

2.5

Strategies for Computational Efficiency

Investigating scaling in the immune system requires calibrating our ODE models
to data from multiple species. We have data for 23 different species comprising
83 individual birds. The samplers are run for 30,000 iterations for each and every
individual. Hence the complete Bayesian inference process involves millions of calls
to our ODE solvers. We use a number of techniques to ensure that our computations
are efficient.

1. We use the computationally efficient Gibbs update steps whenever the full
posterior conditional distributions are known and use Metropolis-Hastings acceptance steps when the full conditional distribution is not available. The
posterior distribution of ODE parameters at the individual level of the hierarchical Bayesian model does not have an analytic closed-form solution. Hence
we use the Metropolis-Hastings sampler to update the the parameters at the
individual level. At all other levels of the hierarchical Bayesian model, we are
able to derive the full conditional distributions and hence we use Gibbs update
steps.
2. ODE solvers use error tolerance thresholds to calculate how much a solution
changes from one step of the solver to the next and to determine when to
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stop. The two ways of determining error are relative error and absolute error.
Smaller error thresholds lead to more accurate solutions but also lead to more
solver steps increasing execution time. Hence these error thresholds represent
tradeoffs between accuracy and computational efficiency. We experimented
with different values of error tolerance thresholds and ultimately chose 1e-3 for
the relative error threshold and 1e-6 for the absolute error threshold.
3. Inference via MCMC is a sequential iterative process where the computations
in each step depend on results in the previous step. This sequential procedure increases the computational complexity of our programs. However there
are computations within an iteration that can be efficiently parallelized. In
our case, each iteration of the MCMC procedure generates candidate solutions
which are then passed to the different solvers representing different individual
birds. The computation done by the ODE solver for each individual is independent of computations done for other individuals. Hence we parallelize these
simultaneous ODE calls by using the MATLAB construct for parallel for-loops
(parfor), which runs these on multiple cores of the same machine.
4. Finally, the choice of dispersion of the proposal distribution represents tradeoffs between thoroughness of search through the parameter space and computational efficiency. If the variance of the proposal distribution is very large,
then the MCMC algorithm can sample from far away regions in the parameter
space. However a large proportion of proposed moves will also be rejected since
they are likely to be in regions that represent infeasible solutions. Similarly if
the variance of the proposal distribution is very small, then the sampler would
move around the parameter space slowly which would lead to computational
inefficiency. We experimented with different values of variance of the proposal
distribution and chose a value of 0.01 for the standard deviation on the log
scale.
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Figure 2.1: Screenshot of graphical user interface to solve ODEs and plot model fits
to data.

Figure 2.2: Screenshot of tool to generate best-fit ODE parameter estimates while
being calibrated to experimental data.
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2.6

Tools for Analysis and Modeling

We created a number of tools to facilitate our analysis of data and model results that
have been made available online [33]. We expect these tools to be helpful to other
researchers in the modeling community. Some of the tools we developed are:

1. We implemented graphical user interfaces in MATLAB that helped us solve
ODEs and plot model fits to data. This tool helped us visualize the effects of
changing ODE parameters on model fit to data. A screenshot of the interface
is shown in Fig. 2.1.
2. We developed a tool that generated best-fit ODE parameter estimates while
being calibrated to experimental data. This tool has a graphical user interface
which modelers can use to input different initial guesses and parameters for
solvers. The tool helped us investigate the effects of different initial guesses on
best-fit model parameters. A screenshot of the tool is shown in Fig. 2.2.
3. Finally, the code implementing the hierarchical Bayesian models was made
efficient, extendable and modular so that we could: a) add an arbitrary number
of species into the model, b) investigate different levels of hierarchy, and c)
investigate different hierarchical groupings of species. This necessitated the use
of special data structures. The choice of data structures and implementation
was also influenced by the unique constraints imposed by parallelizing the code
to run on multiple cores.
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Chapter 3
Scale invariance of immune system
response rates and times

3.1

Abstract

Most biological rates and times decrease systematically with increasing organism
body size. We use an ordinary differential equation (ODE) model of West Nile Virus
in birds to show that pathogen replication rates decline with host body size, but natural immune system (NIS) response rates do not change systematically with body
size. The scale invariant detection and response of the NIS is surprising since the
NIS has to search for small quantities of pathogens through larger physical spaces in
larger organisms, and also respond by producing larger absolute quantities of antibody in larger organisms. We hypothesize that the NIS has evolved an architecture
to efficiently neutralize pathogens. We investigate three different hypothesized NIS
architectures using an Agent Based Model (ABM). We find that a sub-modular NIS
architecture, in which lymph node number and size both increase sublinearly with
body size, efficiently balances the tradeoff between local pathogen detection and
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global response. This leads to nearly scale-invariant detection and response consistent with experimental data. Similar to the NIS, physical space and resources are
also important constraints on distributed systems, for example low-powered robots
connected by short-range wireless communication. We show that the sub-modular
design principles of the NIS can be applied to problems such as distributed robot control to efficiently balance the tradeoff between local search for a solution and global
response or proliferation of the solution. By demonstrating that the lymphatic network of the NIS efficiently balances local and global communication, we suggest a
new approach for Artificial Immune Systems (AIS) that uses a sub-modular architecture to facilitate distributed search. This chapter was co-authored by Melanie
E. Moses (Department of Computer Science, University of New Mexico). It was
published in Swarm Intelligence, Volume 4, 2010, pp. 301-318. Copyright c 2010
Springer Science+Business Media.

3.2

Introduction

Many emerging pathogens infect multiple host species [8], and multi-host pathogens
may have very different dynamics in different host species [9]. Understanding how
quickly pathogens replicate and how quickly the natural immune system (NIS) responds is important for predicting the epidemic spread of emerging pathogens. We
show that pathogen replication rates decline systematically with increasing host body
size, but NIS response times do not increase significantly. We discuss how the decentralized architecture of the immune system facilitates parallel search, enabling NIS
response times that do not increase substantially with body size.
The NIS solves a search problem in both physical space and antigen space. For
the pathogens considered here, the length of the search is determined by the time it
takes for a cognate B cell to encounter antigen. Encounter times depend on the size
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of the physical space in which the search occurs. This is a difficult search problem
since very rare antigen specific NIS cells have to search for small quantities of antigen
throughout the body. For example, a mosquito injects 105 live virus particles into a
vertebrate host that has billions or trillions of cells [34]. The research we describe here
suggests that the time for the immune system to detect and neutralize the pathogen is
nearly independent of the size of the organism. We call this scale-invariant detection
and response.
This is counter-intuitive, since if we inject a sparrow and a horse with the same
amount of pathogen, the immune system of the horse has to search a much larger
physical space to find the pathogen, compared to the sparrow. This research models
how different potential architectures of the lymphatic network enable the NIS to
mount an effective immune response that neutralizes pathogens in time that is independent of host body size. Physical space and resource limitations can also constrain
Artificial Immune Systems (AIS). Our research shows how the optimal design of such
AIS can be informed by architectural strategies employed by the NIS.
In addition to the immune system having to search larger spaces in larger organisms, larger body size may be expected to slow immune system response times
because the metabolic rate of cells is lower in larger species [12]. The metabolic rate of
each cell is constrained by the rate at which nutrients and oxygen are supplied by the
cardio-vascular network. The rate at which this network supplies nutrients to each
cell (Rcell ) scales as the body mass (M ) raised to an exponent of -1/4: Rcell ∝ M −1/4
such that individual cellular metabolic rates decrease as the body mass increases
[11, 12]. The metabolic rate of a cell dictates the pace of many biological processes
[12]. This could affect NIS search times by reducing movement and proliferation of
immune cells [6]. Rates of DNA and protein synthesis are also dependent on the cellular metabolic rate and could influence the rate at which pathogens replicate inside
infected cells [9].
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Table 3.1: Four scaling hypotheses of pathogen replication and immune system response rate [6]
H1: Pathogen replication rate ∝ M 0
NIS search time ∝ M 0
H3: Pathogen replication rate ∝ M 0
NIS search time ∝ M −1/4

H2: Pathogen replication rate ∝ M −1/4
NIS search time ∝ M 0
H4: Pathogen replication rate ∝ M −1/4
NIS search time ∝ M −1/4

The possibilities that NIS cells and pathogens may move and proliferate at speeds
independent of mass (∝ M 0 ) or proportional to cellular metabolic rate (∝ M −1/4 )
lead to four hypotheses, shown in Table 3.1, as originally proposed by Wiegel and
Perelson [6].

We combine an ordinary differential equation model, an Agent Based Model
(ABM) and empirical results from experimental infection studies on West Nile Virus
(WNV) [1, 2, 3] in what is the first test that we are aware of, examining the effects
of body size on pathogen replication and immune system response rates. Our results
are consistent with H2: pathogen replication rate ∝ M −1/4 and NIS rates ∝ M 0 .

The remainder of the paper is organized as follows: Section 3.3 gives an introduction to the relevant immunology; our statistical methods are outlined in Section 3.4;
Section 3.5 discusses an ordinary differential equation model of pathogen growth and
immune response; Section 3.6 discusses the difficulties faced by the NIS in searching
space; we use an ABM to derive scaling relations for NIS cell detection and migration
times in Section 3.7; the results are summarized in Section 3.8; Section 3.9 explains
how a sub-modular NIS architecture balances fast search times and fast communication to recruit NIS cells, leading to scale invariant detection; Section 3.10 discusses
the applications and implications for this work in distributed AIS using an example
of multi-robot control, and lastly we make concluding remarks in Section 3.11.
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3.3

A Brief introduction to the immune system

The NIS has two main components: the innate immune system and the adaptive
immune system. The innate immune system is the first line of defense of an organism and consists of complement proteins, macrophages and dendritic cells (DC) [35].
The adaptive immune system consists of T helper cells, B cells and cytotoxic T cells.
The area of tissue that drains into a lymph node (LN) is called its draining region
(DR). The lymphatic system collects extra-cellular fluid called lymph from tissues
and returns it to blood [35]. DCs sample the tissue in DRs for pathogens, and upon
encountering them, migrate to the nearest LN T cell area to present antigen to T
helper cells. Cognate T helper cells specific to a particular pathogen are very rare (1
in 106 NIS cells) [36]. Upon recognizing cognate antigen on DCs, T helper cells proliferate and build up a clonal population in a process called clonal expansion. While
proliferating, T helper cells also migrate to the LN B cell area to activate B cells.
Cognate B cells specific to a particular pathogen are also very rare. They need to
recognize cognate antigen on follicular dendritic cells and also need stimulation from
cognate T helper cells. After recognition, cognate B cells undergo clonal expansion
and differentiate into antibody-secreting plasma cells [35].
This difficult search through the large physical space is facilitated by infected site
inflammation, chemokines and preferential expression of adhesion molecules which
guide NIS cells to sites of pathogen invasion [35]. The infected site LN recruits
NIS cells from other LNs and blood through high endothelial venules. We refer to
the recruitment time as communication overhead between LNs. Some pathogens do
not invoke all the arms of the immune system, e.g. some bacteria are efficiently
eliminated by the innate immune system. We focus here on pathogens, like WNV,
that elicit an antibody response. However, the arguments put forward in this paper
would apply also to other pathogens that spread systemically throughout the body
and evoke a cytotoxic T cell or other response (see Section 3.9).
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We are interested in the physical structure of the NIS, and we hypothesize that
evolutionary pressures have shaped NIS architecture to minimize the time taken to
unite rare antigen-specific NIS cells with their pathogens. This requires both rapid
detection of the initial pathogens and also rapid clonal expansion to produce sufficient
T helper cells to activate a critical number of B cells. These B cells will then undergo
clonal expansion and differentiate into antibody-secreting plasma cells. Hence this
paper focuses primarily on the uptake of antigen by DCs in DR, recognition of antigen
on DCs by T cells in LN, the subsequent process of clonal expansion and recruitment
of B cells from other LNs.

3.4

Statistical methods

We use ordinary least squares (OLS) regression to test whether our model predictions
are consistent with hypothesized scaling relationships and, where possible, biological
measurements. We calculate the r2 value, where r is the Pearson correlation coefficient and the r2 quantifies the proportion of variation that the independent variable
explains in the dependent variable. We test how empirical data from literature and
results of our simulation scale with mass by taking the logarithm of both variables
and doing an OLS regression. We report whether the scaling exponent is consistent with -0.25, 0, or both. We test for significance at the alpha = 0.05 level. The
mean is reported after testing all log-transformed datasets for normality using the
Jarque-Bera test [37].
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3.5

An ordinary differential equation model for
viral dynamics

A standard Ordinary Differential Equation (ODE) model was developed to observe
how viral proliferation rates and immune response rates scale with body size, and
model results were parameterized to empirical levels of virus in blood [38]. Data on
viral proliferation was taken from studies which used the same West Nile Virus strain
to experimentally infect 25 different species with body mass ranging from 0.02 kg
(house finch) to 390 kg (horse), and the viral load was monitored each day in blood
serum (reported in plaque forming units - a measure of the number of infectious
virions) over a span of 7 days post infection (d.p.i) [1, 2, 3]. In the model, p = rate
of virion production per infected cell, γ = innate immune system mediated virion
clearance rate, ω = adaptive immune system proliferation rate, and tpv = time to
attain peak viral concentration. Equations (1) to (4) are shown below

dT
= −βT V
dt

(3.1)

dI
= βT V − δI
dt
dV
= pI − c(t)V
dt


γ , t < tpv
c(t) =
 γeω(t−tpv ) , t ≥ tpv

(3.2)
(3.3)
(3.4)

Target cells T are infected at a rate proportional to the product of their population
size and the population size of virions V , with a constant of proportionality β. The
loss in the target cell population is balanced by a gain in the infected cell population.
Infected cells I die at a rate δI. Virions are produced by infected cells at a rate p
and cleared by the immune system at the rate c(t)V . The action of the immune

24

Chapter 3. Scale invariance of immune system response rates and times

system is decomposed into an innate response (γ) before the virus concentration
attains a peak, and an exponential adaptive immune response after peak due to
clonal expansion characterized by a proliferation rate ω. This paper focuses on p as
pathogen replication, and γ and ω as immune system response.
Empirical data show that time to peak viral concentration (tpv , time between
infection and peak viral concentration in blood) for WNV empirically occurs between 2 - 4 days post infection (Fig. 3.1) [1, 2, 3]. If this peak were due to target
cell limitation, then we would expect tpv to increase with host mass M since larger
animals have more target cells. However, tpv is likely to be determined by WNV
specific antibodies, which have a critical role in WNV clearance [39]. If the peak is
determined by a threshold presence of antibodies, then it implies that tpv is determined by the time for cognate B cells to recognize antigen, proliferate and produce
antibodies: tpv = tdetect + tprolif . Empirically, tpv is independent of host mass [1]. The
time tpv is highly conserved, ranging only between 2 and 4 days post infection across
different hosts that range in mass from 0.02 kg (house finch) to 390 kg (horses). Since
there is no statistically significant relationship between tpv and M (Fig. 3.1)(p-value
testing significance of the slope - 0.35, 95% CI on slope - [-0.037, 0.0607]), then the
data are consistent with the hypothesis that tpv ∝ M 0 . Hence empirical data for
WNV supports the hypothesis that NIS response rates are independent of M . One
explanation that has been proposed is preferential metabolism, i.e. LNs are supplied
energy at a rate which is independent of host body mass so that the metabolic rates
of B cells and T cells in LN are independent of mass [6].
Other empirical data suggests that pathogen replication rates scale as M −1/4 for
a variety of pathogens in a variety of hosts, including WNV in birds and mammals
[9]. The Cable et al study shows that times for a pathogen to cause symptoms or
death is proportional to M 1/4 (where times are inverses of rates, mean exponent =
0.21, Table 1, [9]). Together, these observations reject all hypotheses in Table 3.1
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Figure 3.1: Plot of log10 tpv (empirically measured time between infection and peak
viral concentration in blood, units of day) vs. log10 host body mass M . p-value
testing significance of the slope = 0.35, 95% confidence interval on slope = [-0.037,
0.0607], data from [1, 2, 3]
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Figure 3.2: Left Panel: plot of log10 γ (model estimated innate immune system
mediated pathogen clearance rate, units of day −1 ) vs. log10 host body mass M (pvalue testing significance of the slope = 0.4238, 95% confidence interval on slope
= [-0.04, 0.146]). Right Panel: plot of log10 ω (model estimated adaptive immune
system cell proliferation rate, units of day −1 ) vs. log10 host body mass M (p-value
testing significance of the slope = 0.7242, 95% confidence interval on slope = [-0.347,
0.4319])

except H2: pathogen replication declines with M −1/4 and immune response times are
invariant with respect to M . Ideally we would test all four hypotheses simultaneously
using the ODE model described by Equations (1) to (4). However, the ODE has too
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Table 3.2: Estimated ODE model parameters for great-horned owl (where PFU is
Plaque Forming Units)
!



 
 
 



1
1
1
1
1
1
V0 PFU
β
p
δ
γ
ω
t
pv
mL
PFU ∗day
PFU∗day
day
day
day
day
mL
2.95

10−7

524.97

1.19

91.99

2.7

3

many parameters to simultaneously test both hypotheses without overfitting the
data. Since our main goal is to determine the scaling of the NIS response rates
and times, we fit the data by choosing initial parameter estimates consistent with
pathogen replication rates scaling as M −1/4 , and then fit the model to the data.
The ODE model was fit to the viral load data for each of 25 species [1, 2, 3] for
days 1 - 7 and the model parameters were estimated using non-linear least squares
regression. The Berkeley Madonna R [32] software package was used to generate the
fits and we assigned the parameter value to the mass of the species to do an OLS
regression. The scaling relations found were: p ∝ M −0.29 (the predicted exponent of
-0.25 is in the 95% CI, r2 = 0.31, p-value testing significance of slope = 0.0038). The
innate immune system mediated pathogen clearance rate (measured day −1 , γ) and
adaptive immune system cell proliferation rate (measured day −1 , ω) were independent of host mass M (Fig. 3.2)(p-values testing significance of the slope - 0.4238 and
0.7242 respectively, 95% CI on slope - [-0.04, 0.146] and [-0.347,0.4319] respectively).
A sample parameter estimate and model prediction is shown in Table 3.2 and Fig.
3.3.
These findings from our ODE model and empirical data are consistent with hypothesis H2: pathogen replication rates decline in larger hosts, but immune response
is independent of host mass (scale-invariant detection and response). This raises
the question: what mechanisms make NIS rates independent of host body mass and
metabolism? The problem of slower metabolism in larger hosts can be circumvented
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Figure 3.3: A sample plot of virus concentration in blood vs. time post infection
(solid line - predicted ODE model output, circles - actual experimental data for a
great-horned owl (data from [1]). Y axis - virus concentration in log10 PFU/mL of
blood, X axis - days post infection.

in immune response if LNs have privileged metabolism, i.e. they consume energy
which is independent of host mass [6]. However, even if immune system cells are not
constrained by the lower mass specific metabolism in larger organisms, it remains to
be explained how larger spaces can be searched in invariant time.

3.6

Searching for a needle in a haystack

The NIS is confronted with a very difficult search problem. Extremely rare B cells
or T cells specific to a particular antigen (1 antigen-specific T cell in 106 T cells)[40]
search for initially rare antigen in localized tissue. A constant number of virions is
injected into a host by mosquitoes, regardless of host size, for WNV [34] and other
pathogens spread by mosquito vectors. Our analysis of the ODE model and the
empirical tpv suggest that the NIS in bigger organisms can find this fixed number of
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virus particles in approximately the same time as in smaller organisms, i.e. a horse
finds those virions in a body (i.e. ‘haystack’) 10,000 times larger than a sparrow’s
body, but in the same time.
By way of introduction we define a completely modular system as one that is composed of self-contained units that are a fixed size and do not need to communicate,
and a module as a LN and its DR. To simplify our models, we assume that each
LN has a single DR and a DR drains into a single LN. Perfectly parallel search is
easily achievable if an immune response is completely modular at the LN level and
systemic communication in the immune system does not generate more overhead in
larger systems. Completely modular systems have no overhead of communication
and hence achieve perfectly parallel search [41] since search is in a space of the same
size and is replicated in parallel. However, experimental evidence suggests that the
NIS is not modular at the LN level (see Section 3.9) [42, 7, 43].
A conceptually similar concept of modularity has been proposed in protecton
theory [44]. A protecton is a modular unit of protection consisting of 107 B cells of
different specificities per mL of volume and is iterated proportionally to the size of
the organism, i.e. if one samples 1 mL of a tadpole and 1 mL of an elephant, the
same set of 107 B cells will be found in each, but the elephant will have more copies of
the protecton. This modular design reduces the time taken to build up a population
of effector cells by clonal expansion. The protecton is a theoretical concept that the
density and diversity of lymphocytes is constant across organisms. However, theory
does not address how the lymphocytes constituting a protecton migrate through the
body or how much communication occurs between lymphocytes or LNs. This further
motivates the question of investigating whether there is modularity at the level of
LN that would help to parallelize the search process. Sections 3.7 and 3.8 explore
the empirical architecture of LN organization, and explain why a purely modular
architecture is not optimal.
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3.7

Agent based model to explore how LN size
affects NIS response time

The general model of immune system dynamics in the LN and its DR are shown in
Fig. 3.4 and summarized as follows:

virus

t

Tcell,DC
t detect

DC
detect

Langerhans
Dendritic
Cell

DC
t migrate
migrate

Langerhans
Dendritic
Cell

T helper
cell

Langerhans
Dendritic
Cell

virus

Figure 3.4: Immune system dynamics within a lymph node and its draining region.

1. Stage 1: DCs randomly search for antigen in a local DR. The time taken to
detect antigen is denoted by tDC
detect .
2. Stage 2: DC migrates to a local LN T cell area along a chemotactic gradient.
The time taken to migrate is tDC
migrate .
3. Stage 3: Antigen-specific T cell in a LN detects antigen on DC and the time
cell,DC
taken to detect is tTdetect
. T cells then activate cognate B cells which undergo

clonal expansion to produce antibody-secreting plasma cells.
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Table 3.3: The parameters used in the agent based model together with a short
description of their role and default value (L - literature, F - fit to data)
Description

Value

Source

Side length of cubic compartment (DR) 1000µm to 4000µm L [42]
Side length of cubic compartment (LN)

250µm to 1000µm

Duration of a time step

60 sec

Number of antigen specific B cells in a
lymph node of 106 B-cells

L [42]
F

1

L [40]

1250/mm3

L [45]

100

L [34]

Radius of T cell

10µm

L [40]

Radius of antigen-presenting DC

30µm

L [40]

Speed of T cell

0.1664µm/sec

L [40]

Speed of antigen-presenting DC in LN

0.0416µm/sec

L [40]

Speed of antigen-presenting DC in DR

0.0832µm/sec

L [46]

Sweep and sense distance of antigenpresenting DC (measured from cell center)

50µm

L [40]

Density of DC in DR
Amount of antigen in DR

Total time to detect antigen is given by
T cell,DC
DC
tdetect = tDC
detect + tmigrate + tdetect

(3.5)

We consider the time spent by the draining infected site LN in recruiting other
NIS cells to it as the time spent in communication (tcomm ) (see Section 3.9).
We use an ABM to investigate how organization of the lymphatic network minimizes the time to detect antigen tdetect and tcomm , leading to scale-invariant detection
and response.
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We note that the total volume of organs and fluids in mammals both scale proportional to M [47, 11], so in our models, we assume that LN volume and the total
volume of lymph in the entire body are both proportional to M . Thus, the number
of LN multiplied by the volume of each LN is proportional to M . Additionally, the
volume of a DR is determined by M (which is proportional to body volume, given
that tissue density is constant across animals)[47] divided by the number of LN, i.e.,
for a fixed size M , more LN result in a smaller DR for each LN.
In order to explore how the spatial arrangement of LNs affects time to detect
antigen, we use the CyCells [29, 30] ABM to simulate viral replication in a 3D compartment representing the LN and DR. We simulated DCs, T cells, viruses and LNs,
and explicitly modeled DC migration from tissue to LN along a chemotactic gradient, and random walk of DC and T cells in LN T cell area. The model parameters
are summarized in Table 4.1.
The assumptions that we make are: a) initially, we ignore migration of antigen
specific B cells from other LNs. We consider how such systemic responses change the
NIS architecture in the next section; b) there is a fixed chemotactic gradient for DCs
to migrate into the LN; c) for simplicity, we ignore pathogen replication in the tissue
since WNV does not replicate until after it spreads to the LN and other organs; d)
DCs and T cells perform random walks in LN T cell area [48]; and e) LNs have
preferential metabolism [6], i.e. inside a LN, NIS cells have speed and proliferation
rates that are invariant with host mass M .

3.8

Results

We first use an ABM to calculate the detection and migration times in Eqn. (5)
for mice and then show how each of these times scale with LN and DR dimensions.
We then use these scaling relations to derive analytical expressions for detection,
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Table 3.4: Simulated values in mice for DC antigen detection, DC migration and
DC-T cell interaction
Times
Dimensions (DR, LN)
Value (simulation)
tDC
detect

4000µm, 1000µm

Mean = 26 minutes,
SD = 32 minutes, 10
simulations

tDC
migrate

4000µm, 1000µm

Mean = 3.7 hours, SD
= 1.3 hours, 10 simulations

cell,DC
tTdetect

4000µm, 1000µm

Mean = 15.1 hours,
SD = 6 hours, 10 simulations

Table 3.5: Scaling relations for time for DC antigen detection, DC migration and
DC-T cell interaction (lDR = length of DR compartment, lLN = length of LN compartment).
Times

Dimensions (DR)

Scaling Relation Statistics

tDC
detect

1000µm, 2000µm, 4000µm

∝ (lDR − lLN )0

p > 0.05

tDC
migrate

1000µm, 2000µm, 4000µm

∝ (lDR − lLN )1

r2 = 0.97, p < 0.001

cell,DC
tTdetect

1000µm, 2000µm, 4000µm

0
∝ lLN

p > 0.05

+
+

§

migration and communication times for three hypotheses of LN organization.

Table 3.6: Scaling relations for LN and DR parameters and how tDC
migrate depends on
DR and LN dimensions (N - number of LNs, Vlymph - volume of lymph, VLN - volume
of LN). § - taken from empirical data [7]
Vlymph ∝ VLN
N ∗ VLN

VDR ∝ M/N

tDC
∝ tcomm ∝
migrate
2
lDR − lLN
M/VLN

Model 1 M 1

M1

M0

M0

M0

M1

Model 2 M 0

M1

M1

M1

M 1/3

M −2

Model 3 M 1/2§

M1

M 1/2

M 1/2

M 1/6

M −1/2

LN
Architecture

N
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3.8.1

The base case model of a typical lymph node and scaling up

A DR was simulated as a cubic compartment of side 4000µm with a cubic LN of
length 1000µm. The mean time taken by DCs to detect antigen and the time taken
by an antigen-specific T cell to recognize antigen on DC are shown in Table 3.4 (due
to the prohibitively high execution time of the ABM, we took the average of 10 model
realizations). These are in agreement with experimental observations in mice [40].
T cell,DC
DC
The total time to detect antigen (tdetect = tDC
) is then around
detect + tmigrate + tdetect

19 hours. This is in agreement with experimental studies in mice [49] and consistent
with our observation that peak viral concentration occurs in day 2 to 4 for WNV
across organisms, given our hypothesis that the peak occurs due to WNV-specific
NIS cells, which must first have come into contact with WNV in the LN.

The DR and LN regions were then scaled up and we observed how DC detection,
migration and T cell interaction times scaled with the size of the DR and LN. We
simulated 3 cubic DRs: DR of length 1000µm with LN of length 250µm, DR of
length 2000µm with LN of length 500µm, and DR of length 4000µm with a LN of
length 1000µm. The observed scaling relations are in Table 3.5 and are consistent
with DC migration time scaling linearly with the mean distance from DR to LN.
The time for DC to detect antigen specific T cell in LN was found to be uncorrelated
with the size of the LN.

We now explore 3 competing hypotheses of lymphatic system organization (Fig.
3.5).
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Figure 3.5: The 3 different hypotheses of scaling of lymph node size and numbers.
(1) Completely Modular Detection Network: base organism with 2 LNs and another
organism 4 times as big with 4 times the number of lymph nodes each of the same size
as the base organism. (2) Non-Modular Detection Network: organism 4 times bigger
has the same number of LNs but each is 4 times bigger. (3) Hybrid Sub-Modular
Detection Network: organism 4 times bigger has more LNs each of which are also
bigger.

3.8.2

Model 1: Completely modular detection network

In our first model, we assume that the lymphatic network forms a completely modular
network containing LN of constant size and number of LN proportional to organism
size M . Using the scaling relationship for tDC
migrate from Table 3.5 and noting that in
this model the LN and DR dimensions do not change with organism size gives us
0
tDC
migrate ∝ M . Since the ABM predicts that detection times in LN do not depend on

LN dimensions (Table 3.5) we have tdetect ∝ M 0 and hence the completely modular
architecture gives us perfect scale-invariant detection. The predicted relations are
summarized in Table 3.6.

35

Chapter 3. Scale invariance of immune system response rates and times

3.8.3

Model 2: Non-modular detection network

The second model is the other extreme, that LNs are arranged in a detection network
with a constant number of LN (all animals have the same number of LNs, however
the size of LNs is larger in larger animals). In this model, the DR volume increases
proportional to organism mass, and the average distance that a DC has to travel
from the DR to the LN increases with organism mass as M 1/3 (Table 3.6). Hence
1/3
tDC
. Since DC migration times are approximately 4 hours in mice, this
migrate ∝ M

model predicts that DC migration times in horses (which are 25,000 larger than mice)
will be 30 times more than that in mice. This would necessitate migration times that
are 5 days in horses and greater than the total observed time for antibody response.
Hence the hypothesis of complete lack of modularity in the NIS is inconsistent with
observations.

3.8.4

Model 3: Hybrid sub-modular architecture

This architecture lies midway between Model 1 and Model 2. In this model LNs
increase in both size and in numbers as animal size increases, and so does the size of
1/6
the DR. Table 3.6 gives the predicted relation for tDC
. This will lead to
migrate ∝ M

migration times that are only 5 times longer in horses (around 20 hours) than in mice.
It is not implausible that detection should take so long in a horse, and these slight
increases in detection time might be compensated for by slower rates of exponential
growth by the pathogen, as predicted by our ODE model (Section 3.5). Hence
the sub-modular architecture produces detection times which are consistent with
our empirical observations (scale-invariant detection), since the difference between 4
hours and 20 hours cannot be resolved on the basis of measurements of viral load
taken every 24 hours.
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3.9

Sub-modular architecture balances tradeoff
between local and global communication

The limited published empirical data that we could find suggest that the mammalian
NIS has a hybrid sub-modular architecture (Model 3). There is a trend of increasing
LN size and number as animal size increases, for example, 20g mice have 24 LN
averaging 0.004g each, and humans are 3000 times bigger and have 20 times more
LN, each 200 times bigger [42, 7]. Data from elephants (with LN approaching the
size of an entire mouse) and horses (with 8000 LN) also support the hypothesis that
LN size and number both increase with body size (Model 3) [43, 7]; however, data
for more species are required to statistically reject any of our 3 models.
We hypothesize that the NIS is submodular (consistent with Model 3) because it
is selected not just to minimize time to detect pathogens (achieved by Model 1), but
also to minimize the time to produce a sufficient concentration of antibody in the
blood (Abcrit ). A horse 25,000 times larger than a mouse must generate 25,000 more
absolute quantities of antibody (Ab) in order to achieve the same concentration of
antibody in the blood (where blood volume is ∝ M )[47]. A fixed antibody concentration is required to fight infections like WNV that spread systemically through the
blood. We can now consider that the NIS has evolved to minimize two quantities:
the time to detect antigen (tdetect ), and the time (tproduce ) to produce Ab, where Ab
is proportional to M (Ab is the absolute quantity of antibody required to neutralize
the pathogen in blood).
In all pathogens which evoke the adaptive immune system, the rate limiting step
is the recognition of antigen on DCs by antigen-specific T helper cells within the LN
T cell area [36]. The time taken in this recognition step impacts other downstream
processes like activation of B cells since T helper cells activated by DCs must migrate
to the B cell area to activate B cells. If organisms of all body sizes activated the
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same number of initial B cells prior to clonal expansion, the time for a fixed number
of B cells to produce Ab would be ∝ log2 M (since B cells reproduce exponentially
through clonal expansion). For example, since it takes 4 days of exponential growth
of activated B cells to produce sufficient anti-WNV neutralizing antibody in mice [39],
then the corresponding time for a horse would be more than 2 months, should the
same number of initial B cells be activated prior to clonal expansion. This conflicts
with empirical data on horses [2]. We assume that the NIS of larger organisms has
to activate a larger number of initial B cells (Bcrit ) ∝ M , in order to build up the
critical density of antibodies in a fixed period of time. We now ask how the NIS can
activate Bcrit in our three models.

In Model 1, LNs are a fixed size, and therefore contain a fixed number of B
cells, and the smallest LNs (e.g. in mice) contain on the order of a single B cell
that recognizes any particular pathogen. Thus, activating Bcrit to fight an infection
like WNV that is initially localized in a single DR, requires recruiting B cells from
distant LN. We consider this activation of B cells from remote LN as communication
overhead. In general, the number of LNs that a single infected site LN has to
communicate with (Ncomm ) in order to recruit more B cells is proportional to the
amount of antibody required to neutralize the pathogen divided by the number of B
cells resident in a LN (N umBcell ): Ncomm ∝ Ab/N umBcell . Noting that Ab ∝ M and
N umBcell ∝ VLN we have Ncomm ∝ M/VLN

The rate at which new B cells from other LN enter into infected site LN through
the blood or lymphatic vessels (ratecomm ) is proportional to the volume of the LN,
ratecomm ∝ VLN (assuming that a larger LN will have proportionally more high
endothelial venules and hence can recruit at a higher rate). The time spent in
communicating with other LNs and recruiting and activating other B cells (tcomm ) is
then given by
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2
tcomm = Ncomm /ratecomm ∝ M/VLN

(3.6)

Hence in Model 1, there are increasing costs to communicating with other LN
as the organism gets bigger (tcomm ∝ M ); it carries out efficient search but is not
optimized for antibody production.
Model 2 (non-modular detection network) compensates for the limitation of physically transporting NIS cells over larger distances by making LNs bigger in larger
organisms (VLN ∝ M ). This increases the rate of influx of B cells (ratecomm ∝
VLN ∝ M ) and also situates more NIS cells inside the infected site LN. Since all the
necessary NIS cells that need to be activated are within the LN, this architecture has
no communication cost. However, as shown above (Section 3.8.3), Model 2 leads to
1/3
).
DC migration times that are prohibitively long for large animals (tDC
migrate ∝ M

The architecture that strikes a balance between the two opposing goals of antigen
detection (local communication) and antibody production (global communication) is
Model 3 (hybrid sub-modular architecture). It minimizes T = tdetect + tproduce , where
tdetect = time taken to detect antigen, and tproduce = time taken to produce antibody
= tcomm (since the time taken to produce antibodies is equal to the time taken to
recruit B cells or communicate with other LNs; after recruitment starts and cognate
T cells recognize antigen on DCs, T cells can migrate to the B cell area and activate
B cells in parallel to the recruitment process described earlier).
We can solve for the total time (T = tdetect + tproduce ) to detect antigen and
produce B cells using Eq. (7) and the scaling relationship for tDC
migrate from Table 3.5
giving:
T cell,DC
2
T = tDC
+ bM/VLN
detect + a(lDR − lLN ) + tdetect

(3.7)

where a and b are constants, lDR = length of DR, lLN = length of LN, VLN = volume
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of LN, M = organism mass, and N = number of LNs. This becomes
1/3

T cell,DC
2
T = tDC
+ bM/VLN
detect + cVLN + tdetect

(3.8)

1/3

1/3

where c is a constant, and lDR and lLN scale as VDR and VLN respectively since
VLN and VDR scale isometrically, as M/N .
Differentiating with respect to VLN and setting the derivative to zero to find the
minimum T , gives
VLN ∝ M 3/7

(3.9)

Since the amount of lymph is proportional to host body mass (N ∗ VLN ∝ M ), then
N ∝ M 4/7

(3.10)

These predictions are consistent with the few empirical data we were able to obtain. Similar arguments would also apply to other pathogens that spread systemically
throughout the body and need to activate a number of B-cells or cytotoxic T cells
proportional to M . We note that N ∝ M 1/2 was predicted by Perelson and Wiegel
[50], but that analysis did not explicitly consider an optimization to simultaneously
minimize detection time and time to produce the critical number of Ab.
In summary, due to the requirement of activating increasing number of NIS cells
for antibody production in larger organisms, there are increasing costs to global
communication as organisms grow bigger. The semi-modular architecture (Model
3) balances the opposing goals of detecting antigen using local communication and
producing antibody using global communication between LNs. This leads to optimal
antigen detection and antibody production time, and nearly scale-invariant detection
and response.
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3.10

Relevance to artificial immune systems

The natural immune system utilizes an architecture that functions within constraints
imposed by physical space. Physical space is also an important constraint on artificial
immune systems, especially in applications used to connect inexpensive low-powered
sensors using short-range wireless communication [51]. Such spatial networks are
being increasingly used in environmental monitoring, disaster relief and military
operations [51]. These networks might operate under constraints of resource and
physical space, similar to an NIS. Although there are systematic differences between
an NIS and an AIS [52], the design of the AIS can be informed by architectural
strategies employed by their biological counterpart.

3.10.1

Original system

As a concrete example of an application where space is a constraint and scaling of
performance with system size is an important design criterion, we consider an AIS
approach to control multiple robots tasked with obstacle avoidance [53]. The robots
communicate with software agent(s) in a server upon encountering an obstacle. The
agents transmit rule-sets of actions to robots to help overcome their obstacles, and
agents also share information globally amongst themselves by migrating to other
computer servers. Some analogies between this AIS and an NIS are: the obstacle
problem presented by a robot is analogous to an antigen, the rule-set of actions transmitted by an agent correspond to antibodies, the robots are akin to DCs, software
agents correspond to B cells, the computer servers themselves are analogous to LNs,
and the physical area ‘serviced’ by a single computer server corresponds to a DR.
The system is diagrammed in Fig. 3.6 (modified from [53]).
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Figure 3.6: (A) Left Panel: a scaled down version of the multi-robot AIS system. The
shaded regions are artificial LNs (computer servers) and the unshaded regions are the
artificial DR. Light arrows denote communication between robots and servers (local
communication) and bold arrows denote communication between servers (global communication). (B) Right Panel: a scaled up multi-robot AIS system with sub-modular
architecture. Note that the number of artificial LNs and their size (the number of
robots they service and the number of software agents they have in memory) both
increase with the size of the system.

3.10.2

Modifying the original system using a sub-modular
architecture

We are interested in an architecture that minimizes the time taken by a robot to
transmit information about an obstacle (local detection), the time taken by a computer server to transmit back an initial rule-set of actions (local response) and the
time taken by a computer server to communicate good rule-sets to other agents
(global response). There are two potential communication bottlenecks: communication between robots and computer servers, and communication between computer
servers.
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Overcoming the bottleneck in (local) communication between robot and server
requires many small DRs. A bottleneck in (global) server communication requires
a few large servers. If both local and global communication are constrained, the
architecture which balances these opposing requirements is sub-modular, i.e. the
number of servers increases sublinearly with system size and the capacity of each
server (bandwidth, memory and number of robots serviced by each server) increases
sublinearly with system size (shown in Fig. 3.6). The four ways in which communication can be bottlenecked are outlined below:

1. High Capacity Robot Bandwidth, High Capacity Server Bandwidth: Assuming
that robots have high bandwidth to communicate with computer servers and
software agents can communicate with each other over a channel with high
bandwidth, we see that trivially any of the architectures would suffice.
2. Limited Robot Bandwidth, High Capacity Server Bandwidth: Assuming communication between robots and computer servers is a bottleneck mandates a
small fixed size DR, i.e. a computer server servicing a small number of robots
to reduce contention and transmission time. Since communication between
servers is not constrained, we can have the number of servers scaling linearly
with system size, giving Model 1 (completely modular network) as the optimal
architecture.
3. High Capacity Robot Bandwidth, Limited Server Bandwidth: Assuming communication between computer servers is a bottleneck stipulates a fixed number
of computer servers to reduce communication overhead. Since communication
between robots and servers is not constrained, we can have the DR size (number of robots serviced by a single server) and LN size (number of agents in a
single server) scaling with system size. Hence the optimal architecture is Model
2 (non-modular detection network).
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4. Limited Robot Bandwidth, Limited Server Bandwidth: A bottleneck in robot
and server communication demands a small DR and lots of servers, whereas a
bottleneck in server communication requires fewer large servers. The architecture that balances these opposing requirements is Model 3 (hybrid sub-modular
architecture), i.e. the number of servers and their size (number of robots serviced by each server) increases with system size (3.6).

The local communication time within an artificial DR is a function of the number
of robots (d) serviced by a single artificial LN
tlocal = f (d)

(3.11)

The function f will depend on constraints on communication between robots and
servers, influenced, for example, by how robot requests are queued on the server and
the distance over which low power robots can send and receive messages. The global
communication time between artificial LNs is also a function of the number of LNs
in the system (n/d) where n is the total number of robots in the entire system

tglobal = g(n/d)

(3.12)

The function g depends on communication constraints between servers. For low
latency and high bandwidth connections among servers, tglobal may not scale appreciably. However, low power servers distributed in remote environments, may preclude
broadcast communication such that tglobal increases with n/d. An increase in the size
of an artificial LN (and hence the number of robots serviced, d) would reduce tglobal
at the cost of tlocal . The size and number of artificial LNs to balance local and global
communication depends on the precise functions f and g mediating local and global
communication.
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Although we have provided only one example, this research is widely applicable
to other distributed systems AIS applications. In recent work, we have extended our
work to modify peer-to-peer systems with a sub-modular architecture [54].
In summary, understanding the tradeoff between fast search for pathogens and
fast production of antibodies is important for AIS that mimic the NIS. If the goal
of an AIS is only search or detection in physical space with a local response, then a
completely modular design (Model 1) will be optimal. If an AIS searches in physical
space but requires a global response after detection, a sub-modular architecture
(Model 3) optimizes the tradeoff between local search and global response and will
lead to faster search and response times (T = tlocal + tglobal ). Our analysis sheds light
on the relationship between physical space and architecture in resource-constrained
distributed systems.

3.11

Conclusions

Host body size constrains pathogen replication rates due to the physical characteristics of transportation networks that supply infected and normal cells with energy.
Host body size also constrains NIS detection and response times by increasing the
physical size of search spaces. The NIS is comprised of rare antigen-specific immune
system cells that it must utilize to search for initially small numbers of pathogens
localized in a large physical space. The NIS solves this classic search for a ‘needle in
a haystack’ in time that is almost invariant of the size of the organism. The decentralized nature of the lymphatic network also helps in efficient pathogen detection
by acting as a small volume of tissue where DCs can efficiently present antigen to
T cells. The NIS must also respond to the antigen by producing antibodies (in the
case of WNV) proportional to the mass of the organism. From empirical data, that
time also appears independent of body size.
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We use an ODE model to show that NIS response rates are independent of host
body size and pathogen replication rates decrease with body size. We examine three
different hypothesized NIS architectures using an agent based model, to explain the
scale-invariant detection and response times of the NIS. The sub-modular detection
network strikes a balance between the two opposing goals of antigen detection (local
communication) and antibody production (global communication), and is consistent
with observed numbers and sizes of LN. This submodular architecture of the lymphatic network must simultaneously provide systemic protection to the entire body
while protecting each local volume of tissue equally well. Thus, the lymphatic architecture lies between the extremes of the fully centralized cardiovascular network (in
which blood is oxygenated in a single location) and the fully decentralized concept of
the protecton (in which a fixed number and diversity of lymphocytes protects every
volume of tissue).
We demonstrated that a submodular architecture effectively balances the tradeoff between local search for a solution and global distribution of the solution in distributed robot control. In addition to incorporating NIS inspired distributed search
algorithms into AIS, we suggest that AIS can replicate the submodular architecture
used by the NIS to balance the tradeoff between local and global communication.
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Chapter 4
The Value of Inflammatory Signals
in Adaptive Immune Responses

4.1

Abstract

Cells of the immune system search among billions of healthy cells to find and neutralize a small number of infected cells before pathogens replicate to sufficient numbers
to cause disease or death. The immune system uses information signals to accomplish
this search quickly. Ordinary differential equations and spatially explicit agent-based
models are used to quantify how capillary inflammation decreases the time it takes
for cytotoxic T lymphocytes to find and kill infected cells. We find that the inflammation signal localized in a small region of infected tissue dramatically reduces search
times, suggesting that these signals play an important role in the immune response,
especially in larger animals. This chapter was co-authored by Drew Levin, Melanie
E. Moses, Frederick Koster and Stephanie Forrest (Department of Computer Science,
University of New Mexico). It was published in the 10th International Conference on
Artificial Immune Systems (ICARIS), Lecture Notes in Computer Science, Volume
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4.2

Introduction

Rapid search is crucial for an effective immune response: Immune system cells must
find, identify and neutralize pathogens before those pathogens replicate in sufficient
numbers to cause disease or death. The adaptive immune system has a small number of pathogen-specific cells that must search for and neutralize a small number
of initially localized pathogens in a very large tissue space. We investigate how
inflammatory signals accelerate this search.
The adaptive immune response must conduct two “searches” to neutralize
pathogens. First, recirculating antigen-specific T and B cell precursors must interact
with antigen-loaded dendritic cells, and the architecture of the lymph node facilitates
this interaction [55, 54, 26]. The second search is T cells activated in the lymph node
efficiently finding and neutralizing infected cells in tissue with the help of inflammatory signals. In this paper we analyze these two searches in response to influenza
infection in the lung.
CTLs are activated within the infected site LN and are released into the bloodstream where they travel through a branching network of arteries until they reach
a capillary in the lung. Capillaries in infected regions of the lung are permeated by
an inflammatory signal which causes CTLs to exit the capillary and enter the lung
tissue, where a chemokine gradient guides the CTL to infected cells. When CTLs
recognize the antigen displayed on the surface of infected cells, they neutralize those
cells. The information represented by the inflammatory signals is local, and occurs
in an initially small region of the lung surface, possibly as small as a few mm2 in a
100 m2 surface area in a human lung [56]. We ask how much the local inflammatory
signal reduces the time for CTLs to find the site of infection and eradicate the in-
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fluenza pathogen. Without an inflammation signal indicating which capillaries are
near infected tissue, CTLs would have to exit capillaries in random locations and
begin a slow random walk (at speeds measured in microns per minute) through the
large area of lung tissue to search for the site of infection. With the inflammatory
signal, CTLs can exit the relatively fast flow of the circulatory network only when
they are in close proximity to infected cells.
In this paper we describe two sets of models. The first (null) model predicts how
long it would take for CTLs to find infected cells by searching via a random walk
through the entire lung tissue. The second set of models are simplified representations
of how inflammatory signals guide CTL search in real immune systems. This second
set of models is parametrized from experimental data. By comparing predictions of
the null model to the more realistic model with inflammation, we estimate how much
the inflammatory signal reduces the time for CTLs to find and eradicate influenza.
We use ordinary differential equation (ODE) and agent-based models (ABM)
to quantify the value of the inflammatory signal, measured as the decrease in the
time it takes for CTLs to both find and eradicate virus from the lung. The ABM
incorporates the spatial aspect of virus spread and CTL mediated killing of infected
cells, and the ODE model can scale up to realistic cell population sizes. In both cases,
we first model an immune response without inflammatory signals where CTLs exit to
tissue at the first capillary they encounter and search by random walks until they find
a chemokine gradient that guides them to the infected cells. Second, we model an
immune response with inflammatory signals where CTLs exit to tissue only when the
capillary has an inflammatory signal. If there is no signal, CTLs recirculate through
the cardiovascular network until they find an inflamed capillary. We suggest that
localized signals like the inflammatory signal are enormously important to immune
function. Here we take a first step toward quantifying the value of that signal in
terms of time required to get T cells to sites of infection and to control influenza
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infection. This has important consequences for understanding the role of information
signals in immune systems more generally, and also the role that local information
signals can play in other complex biological systems [57, 58] and in artificial immune
systems where decentralized search requires effective use of local signals to solve
computational problems [54, 26].
The remainder of the paper reviews relevant features of the immune system (Section 4.3), outlines our hypotheses (Section 4.4), and describes the models (Sections
4.5 and 4.6). Section 4.5 presents the ODE model and compares its predictions to
empirical data. Section 4.6 uses the ABM to verify some of the ODE predictions
and produce more realistic spatially explicit simulations, including pathogen spread
during the CTL search. We conclude by quantifying how much inflammatory signals
improve immune response in these models.

4.3

A Review of the Relevant Immunology

This study characterizes how a key type of adaptive immune cells (cytotoxic T lymphocytes, also called CD8+ T cells or CTLs) [59] search for and neutralize a common
respiratory tract pathogen (influenza) in the principal target organ, the lung (Fig.
4.1). Among the many immune cells and molecules involved in providing defense
against influenza [60], there is a complex set of interactions to guide CTLs to the
site of infection and to produce chemokines and other information signals to help
contain the infection. We simplify the array of chemokines with a single signal that
causes inflammation and attracts CTLs to site of infection.
Infection begins when influenza virus is inhaled into the lung. It enters epithelial
cells lining the airways and the air sacs (alveoli) of the lung. Epithelial cells initiate
the first line of innate immune defense through the activation of interferon and
the secretion of chemokines to attract inflammatory cells such as macrophages [61].
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Inflammation increases local blood flow to the infected region and amplifies the
chemokine signal. To initiate the adaptive immune response, resident lung dendritic
cells capture virus and carry it to the draining lymph nodes (LN). LNs provide
a dense tissue in which T and B lymphocytes and antigen-loaded dendritic cells
encounter each other efficiently. Antigen-specific CTLs are activated within the LN,
undergo cell division, and leave the LN to enter the blood circulation. We focus on
the response of cytotoxic T lymphocytes (CTLs) because recovery from influenza
pneumonia in wildtype mice has been shown to require neutralization of infected
cells by CTLs [62].
The cardiovascular network in the lung follows the fractal branching of the airways.The branching arterioles end in a capillary network which nourishes the airsacs
(alveoli) of the lung. The capillary density in mouse lung is approximately 5000/cm2
(estimated from [56]). The surface area of a mouse lung is approximately 100cm2
giving 500,000 capillaries in the mouse lung. Capillary density decreases as M −1/4
where M is organism body mass [11, 56] and since humans are 10,000 times larger
than mice, the capillary density in a human lung is 500/cm2 . The surface area of a
human lung is approximately 100m2 and hence the number of capillaries in a human
lung is approximately 5 · 108 .
The CTL flow through the arterial network without any signal to guide them
to the tiny fraction of capillaries near the initial infection. If an activated CTL
reaches an inflamed capillary, it exits the capillary into lung interstitial tissue. The
tissue surrounding inflamed capillaries also contains a chemokine gradient which
the CTL follows to locate infected epithelial cells and reduce viral replication. The
chemotactic signals are composed of cytokines and chemokines which provide a region
of attraction larger than that provided by antigen and infected cells. If an activated
CTL reaches an uninflamed capillary, it may wander short distances through the
capillary network. If it still does not encounter an inflammatory signal, it recirculates
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through the blood and eventually returns to another capillary in the lung. The
recirculation time for mice is 6 seconds and 60 seconds for humans [47].
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Figure 4.1: A region (A of radius r) of infected tissue, chemokines and inflammatory
signals, surrounded by region B which does not have any infected cells, inflammation
or chemokines. CTLs (green hexagons) leave the LN at rate σ and travel through
the branching arteries to capillaries. If capillaries are inflamed (in region A) CTLs
exit capillaries and search for infected cells (small red circles) in lung tissue. If the
capillaries are not inflamed (in region B) the CTLs recirculate.

4.4

Goals and Hypotheses

Inflammatory signals and chemotactic gradients are examples of signals that serve to
guide search processes in the adaptive immune system. We hypothesize that these
and other signals enable the activated immune cells to find and neutralize pathogens
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more quickly than in the absence of such signals. More specifically, we aim to quantify
the benefit provided by the inflammation in the capillaries, which allows circulating
CTLs to know that they have reached a site of infection.
We examine a hypothetical immune response without inflammatory signals (CTLs
searching for infected tissue by randomly walking through lung tissue) and a more
realistic immune response with inflammatory signals (CTLs recirculate through the
arterial network until the presence of inflammation signals them to exit near infected
tissue). We study how long it takes for the first CTL to find the infected region, how
quickly CTLs accumulate in infected tissue, and how many epithelial cells become
infected in a specified time period. We quantify the value of the information signal
as the ratio of these values with inflammatory signal to those values without the
signal. We use ODE and ABM to estimate the value of the inflammation signal.
The ODE can model large numbers of cells, so we use ODEs to compare the value of
the inflammatory signal in mice and humans. We then use an agent based model to
investigate the dynamics of infection growth and spatial interactions between cells
in the mouse.

4.5

Ordinary Differential Equation Model

In this section we analyze how quickly CTLs arrive at the site of infection with
and without an inflamation signal using an ODE model. We represent the region
of infection as a circular area (region A) of radius r of tissue expressing a general
chemotactic signal. This region is surrounded by a region of uninfected tissue (a
concentric circle of radius R (region B)) without inflammation or chemokines.
Any activated CTLs that flow to capillaries in region A will have an inflammatory
signal that causes the CTL to exit the capillary and a chemokine gradient that will
direct those CTLs to infected cells. In contrast, CTLs that arrive in the lung via
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capillaries in region B will have no inflammatory signal and no chemokines to guide
them to the infected cells in region A. We assume that CTLs that exit into tissue
do not go back into circulation.
There are several simplifying assumptions in the ODE model. It ignores viral
replication and assumes that the infected region A is a fixed size. It also ignores
the movement of CTLs inside capillaries, and instead assumes that CTLs either
immediately sense inflammation and exit into tissue or immediately recirculate. The
model also ignores CTL death in the lung.
The dynamics of the system are represented by coupled ODEs. We parameterize
the ODEs to consider two cases. In the first case, CTLs search for virus using only
the random walk (null model). In the second case, CTLs in region A receive an
inflammation signal that allows them to exit and follow the chemotactic gradient,
while CTLs in region B continue to recirculate through the lymph system until they
find an inflamed capillary in region A as in Fig. 4.1.

4.5.1

ODE Model 1: CTL Search Without an Inflammation
Signal

In this scenario there is no signal to direct CTLs to an infected region, therefore
CTLs always exit into tissue as soon as they reach a capillary. The capillaries are
assumed to be uniformly distributed throughout the lung, and a single activated
lymph node is assumed to produce activated CTLS at a fixed rate of σ CTLs per
hour. The infection is in a region of constant radius r, and the lung surface is a
circle of radius R. The time taken for CTLs to circulate through the lymph system
is denoted by trc . The combined system is represented by the following differential
equations:
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Nc
dNc
=σ−
dt
trc

(4.1)

dNw
(R2 − r2 ) · Nc
D · Nw
=
−
2
dt
R · trc
π((2/3(R − r) + r)2 − r2 )

(4.2)

dNf
r2 · Nc
D · Nw
= 2
+
dt
R · trc π((2/3(R − r) + r)2 − r2 )

(4.3)

Equation (4.1) describes the change in the number of recirculating activated CTLs
in the cardiovascular system (Nc ) due to the rate of production of new CTLs in the
LN (σ) and time it takes CTLs to travel to the capilaries (trc ). Since the relevant
time step in this setting is the minimum time taken for CTLs to complete one circuit
through the arterial and venous circulation system (the recirculation time trc ) and
is different from the simulation time step (dt), all rate constants are divided by trc .
Equation (4.2) describes the change in the number of CTLs (Nw ) that are doing a
random walk in tissue and searching for infected cells. The change in Nw is due to the
rate at which CTLs exit into region B from circulation (a fraction of

Nc
)
trc

and the rate

at which these searching CTLs find region A. The fraction of circulating CTLs that
2

2

enter capillaries in region B is given by the relative area of region B ( R R−r
). The rate
2
at which CTLs find region A is calculated as follows: an average CTL in region B will
be at a distance 2/3 from the periphery of region A (obtained by integrating over all
CTLs at each distance in region B). The mean area that this CTL will cover before
reaching region A is given by the quantity π((2/3(R − r) + r)2 − r2 ), and the mean
time in which this area is covered is this quantity divided by the diffusion constant
for random walk (D), again adjusted for the recirculation time. The reciprocal of this
time gives the rate at which a single CTL enters region A. To complete the analysis
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we multiply this quantity by the number of searching CTLs. Finally, Equation (4.3)
describes the change in the number of CTLs (Nf ) that have found infected cells (in
region A). This is composed of the searching CTLs from Equation (4.2) that find the
infected region and the fraction of the recirculating CTLs from Equation (4.1) that
enter capillaries in region A (represented by the area of region A relative to the total
lung area). We use the model to study the arrival of CTLs at the site of infection,
first in the mouse lung and then in the human lung.
In order to numerically integrate Equations (4.1)-(4.3) we first estimate the diffusion rate of CTLs. Since we are not aware of any published values for diffusion
rates of activated CTLs within tissue, we used measured mean square displacements
of T cells within the LN [63]. Following Beauchemin et al. [63], the equation relating
mean square displacement of a random walking particle in two dimensions at time t
√
Γ( 3 )
is given by | m |= 4Dt Γ( 21 ) where | m | is the mean square displacement, D is the
2

diffusion constant and Γ is the gamma function. We estimated D as 56(µm)2 /h in
the LN [63], and we use this value to characterize the random walk in lung tissue.
We estimate the parameter σ from experimental data (detailed in the next section) as 864 activated CTLs per hour, and the time to recirculate (trc ) is 6 seconds
[64]. The area of infection has a radius (r) of 1 mm (personal observation for seasonal
strains in mice) and the total lung surface is represented by a circle with a radius of
10 cm (R) [56].
The model shows that there is a steady state of approximately 2 circulating activated CTL. So few CTLs are in circulation because they exit the LN approximately
1 every 4 seconds and spend only 6 seconds in blood before immediately exiting the
blood to search in the lung. We numerically simulated the ODE system and found
that the time for the first CTL to reach the site of infection (region A) is approximately 12 hours post activation in the LN (Fig. 4.2, Panel A). Approximately 10
CTLs find the infected region at day 5 post activation.
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Next we use ODE Model 1 to predict how quickly CTLs arrive at the infected site
in a human. Human body mass is approximately 10,000 times larger than a mouse.
Human lungs are a corresponding 10,000 times greater area, so R becomes 10 meters
[56]. We assume that the initial area of infection r remains the same 1mm2 . CTL
recirculation time (trc ) increases to 60 seconds [64].
In order to calculate the rate of CTL production from LN (σ) we scale the (σ)
estimated for mice by a factor of M 3/7 following [26]. This scaling assumes that
LNs in larger animals are larger and have more high endothelial venules to release
activated CTLs at a faster rate. From this we estimate σ as approximately 45000
CTLs per hour. Numerically simulating the ODE system, we predict the time for a
CTL to find an infected cell in a human lung as approximately 90 days, which is much
longer than the actual time taken to resolve influenza infections (approximately 10
days) [62].

4.5.2

ODE Model 2: CTL search with an Inflammatory Signal

Here we model an immune response with inflammatory signals. CTLs exit capillaries
and enter lung tissue only when there is an inflammatory signal in the capillary. All
other parameters are identical to ODE Model 1. The system is represented by the
following differential equations:

r2 · Nc
dNc
=σ− 2
dt
R · trc

(4.4)

dNf
r2 · Nc
= 2
dt
R · trc

(4.5)
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Figure 4.2: Row A: The number of circulating CTLs (Nc ) and CTLs that have arrived
at the site of infection(Nf ) vs. time post activation of the first CTL in LN for CTLs
searching without an inflammatory signal (ODE Model 1) for mice (blue, left axis)
and humans (green dotted, right axis). The number of recirculating CTLs reaches a
steady state because once they enter the lung they never recirculate. Row B: Nc and
Nf vs. time post activation for CTLs circulating in the presence of inflammatory
signals (ODE Model 2 fit to experimental data) for mice (blue, left axis) and humans
(green dotted, right axis). Note the difference in y-axis scale between the two rows.

Equation (4.4) describes the change in the number of circulating activated CTLs
circulating in the cardiovascular system (Nc ). (Nc ) changes due to the addition of
new CTLs from the LN at rate (σ), and the loss of CTLs from circulation that
exit capillaries expressing inflammatory signals and enter infected tissue (region A).
Equation (4.5) describes the increase in the number of CTLs that find infected cells.
This is the same as the loss term from the pool of recirculating CTLs from Equation
(4.4).
We fit Model 2 to experimental numbers of CTLs in lung at various time points
post infection for influenza in mice [62]. The fitting procedure found free parameters
that minimized the mean squared error between the model and the data. We only
considered data up to the peak of CTL activation and did not consider the decline
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of CTLs after the infection is cleared.

Model 2 (Equations 4.4 and 4.5) was solved numerically using Berkeley Madonna
[32]. The curve fitter option in Berkeley Madonna (Runge-Kutta 4, step size =
0.0004 sec) was used to establish the best-fit parameter estimates. The curve-fitting
method uses nonlinear least-squares regression that minimizes the sum of the squared
residuals between the experimental and predicted values of Nf .

Next we compared model output for mice and humans. For mice, we fixed r to
1 mm, R to 10 cm, and the recirculation time (trc ) to 6 seconds. We then estimated
the LN rate of output of CTLs (σ). The best fit estimate for σ was approximately
864 activated CTLs per hour. Model output is shown in Fig. 4.2 Panel B (a list of
all ODE model parameters is given in Table 4.1). Numerically simulating the ODE
system, we estimated the time taken for the first CTL to reach infected tissue to
be approximately 15 minutes (Fig. 4.2 Panel B). Approximately 80000 CTLs find
the infected region at day 5 post activation. We modeled CTL search in the human
lung using the same values as in ODE Model 1 (R = 10 meters, trc = 60 seconds
and σ = 45000 CTLs per hour) and numerically simulated the ODE system. The
predicted time for an activated CTL to discover an infected cell in a human lung is
approximately 8 hours, and the number of CTLs that reach the lung by 5 days post
activation in the LN is approximately 190.

In summary, the presence of an inflammatory signal and a chemokine gradient
around infected cells results in a earlier first discovery of infection by activated CTLs
in both mice and humans. In mice, the first CTL with inflammation arrives in 15
minutes compared to 12 hours without it, a 48-fold speedup. The inflammation signal
reduces search time in humans more than in mice: The first CTL with inflammation
arrives in 8 hours compared to 90 days without it, a nearly 270-fold speedup.
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Table 4.1: The parameters used in the ODE and ABM for mice with a short description of their role and default value (§ measured in human cell lines)
Description

Value

Source

Release rate of activated CTLs (σ)

864/h

Fit to data in [62]

CTL recirculation time (trc )

6s

CTL diffusion coefficient (D)

56(µm)2 /h

[47]
Calculated from [63]

Radius of lung area (R)

10cm

[56]

Radius of circle lung infected area
(r)

0.1cm

Personal observation

Length of cubic ABM simulation
compartment

2000µm

Time between infection and secretion §

10.5h

[65]

17.15h

[65]

2.6 virions/h

[65]

Duration of productive infection
ABM virus secretion rate

§

§

Model parameter

ABM CTL sensing radius

10µm

Model parameter

ABM Epithelial cell diameter

10µm

Model parameter

ABM CTL diameter

4µm

Model parameter

Figure 4.3: A snapshot of the CyCells ABM in action. The epithelial cell layer is
made up of healthy cells (dark red), infected incubating cells (green), virus expressing
cells (blue), and dead cells (yellow). The area of lighter red surrounding the infection
shows that free virus particles (semi-transparent white) are present. T-cells (pink)
are seen swarming over locations with high virus concentration.

4.6

Agent Based Model

The ABM extends the earlier results to consider spatial and stochastic effects of CTL
migration and recirculation, also incorporating infection spread and CTL mediated
61
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killing of infected cells. The CyCells [29, 30] modeling tool explicitly represents
healthy cells, infected cells, and CTLs, and represents cytokines, chemokines, and
virus as concentrations. We model the release of virions from infected cells, diffusion
of chemokines and inflamatory signals, and chemotaxis of CTLs up a chemokine
gradient. A screenshot of the graphical representation is shown in Fig. 4.3.

Figure 4.4: Panel A: Plot of the number of recirculating CTLs (Nc ) and CTLs
that have found infected cells (Nf ) vs. time post activation for CTLs only walking
randomly (ABM 1). Panel B: Plot of Nc and Nf vs. time for CTLs only recirculating
(ABM 2). Panel C: Plot of the number of infected cells over time for ABM 1 and
ABM 2. The population bumps in Panel C during the first day post activation are
an artifact of the model initialization scheme and do not affect the final results.

4.6.1

ABM Model 1: Dynamics without Inflammation

We start by modelling a 2mm by 2mm grid with an area of infection that represents
five days of growth in the absence of a secondary immune response. After five
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days, specific CTLs become activated and enter the grid at a random location at
σ = 864/hour, scaled down to adjust for the 4mm2 subset of the 10cm × 10cm area
of the mouse lung. In ABM Model 1, there is no inflammatory signal, so CTLs that
enter the grid immediately exit the capillary and begin a random walk through lung
tissue. Infected cells produce virions which then infect healthy cells. Virus infected
cells are differentiated into two populations: infected cells that are incubating but
not secreting virus, and expressing cells that are actively producing new virions. The
parameters describing rate of infection of healthy cells are taken from a previous study
[65] (summarized in Table 4.1). Our primary results comparing system dynamics
with and without inflammation signals do not depend on these parameters.
The time taken for the first CTL to detect an infected cell is 90 minutes. 33
CTLs find the infection five days post activation (Fig. 4.4 Panel A). There are 4,077
infected cells five days post activation.

4.6.2

ABM Model 2: Dynamics with Inflammation and CTL
Recirculation

Next we study an immune response with inflammatory signals. We simulated an
influenza infection using the same parameters as ABM 1, but allowed CTLs to recirculate until they encountered an inflammation signal. We evaluate the value of the
inflammatory signal by comparing the results of ABM 1 and ABM 2.
The time taken for the first CTL to find an infected cell is 3.3 minutes. The
number of CTLs which find infected cells in 5 days is 111,572 compared to 33 in
ABM 1 (Fig. 4.4 Panel C). The number of infected cells remaining in the simulation
is much lower for ABM 2 (46.7) compared to ABM 1 (4,077). Hence the value of
the inflammation signal is a reduction in the number of infected cells at day 5 (from
approximately 4,077 without an inflammatory signal to approximately 47 with the
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Table 4.2: The effect of inflammation on the time taken by CTLs to first detect
infection, the number of CTLs that arrive in the infected region by day 5 post
activation and the number of infected cells in the simulated lung tissue by day 5 post
activation. ABM means and standard deviations are from three independent runs of
each ABM.
Mice
Time to first detection
Arrived CTLs
Infected cells

Humans
Time to first detection
Arrived CTLs §
Infected Cells §

ODE
ABM
ODE
ABM
ODE
ABM

Without Inflammation
12 hr
90 min ± 31.3 min
10
33 ± 4.6
4,077 ± 518

With Inflammation
15 min
3.3 min ± 1.9 min
80,000
111,572 ± 1,536
46.7 ± 4.7

Benefit of Inflammation
48
27
8,000
3,380
87

ODE
ODE
ODE

Without Inflammation
90 days
0.05
-

With Inflammation
8 hr
190
-

Benefit of Inflammation
270
3,800
-

signal).

4.7
4.7.1

Discussion
Summary of Results

In this study we used ODE and ABM models to quantify how much inflammation of
infected tissue improves the adaptive immune response. This is measured in terms
of three different values: how much the inflammatory signal speeds up the arrival of
the first CTL at the site of infection; how much the inflammatory signal increases the
number of CTLs that find the site of infection five days after CTL activation; and how
much the inflammatory signal decreases the number of infected cells at five days after
CTL activation. We used ODE and ABM models to quantify these improvements in
mice and the results are summarized in Table 4.2. The speed up for the first CTL
to arrive in the infected region in a mouse is tens of times faster in both the ODE
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and ABM models. The number of CTLs that reach the infected region by day five
post activation is thousands of times faster in both models. The ABM includes CTL
mediated killing of infected cells and predicts that with an inflammatory signal, the
number of infected cells at day five is 87 times lower.
We scaled up the ODE model to make the same predictions for the human lung
which is 10,000 times larger than the mouse lung. The ODE models predict that
with an inflammatory signal the speed up in arrival of the first CTL humans is 270
times faster and 3800 times more CTL arrive at the site of infection at day five.
Thus, the inflammatory signal improves the CTL search much more in the human
than in the mouse.

4.7.2

Caveats and Limitations

We have made many simplifying assumptions in our models. We have ignored death
of activated CTLs. We have assumed that LNs produce activated CTLs at a constant
rate. We have ignored the time that activated CTLs spend in transit through a
capillary network before going back into circulation if there is no inflammation.
Because our interest is in the effect of a single signal (the inflammation signal the
causes CTL to exit circulation and enter lung tissue near the site of infection), we
ignore a vast array of signaling mechanisms and complex interactions between innate
and adaptive immune system cells.
However, our assumptions and simplifications do not affect our primary conclusions about the relative speed of CTL search with and without an inflammatory
signal. For example including a death rate of activated CTLs would give us a slightly
higher estimate of the rate at which LNs release activated CTLs (σ) which would
decrease search times with and without an inflammatory signal. Incorporation of a
time dependent rate (σ) would give us more accurate production rates, but, again,
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this would change search times with and without an inflammatory signal in similar
ways. Our conclusions that inflammation greatly speeds up CTL search in the lung
depends primarily on two assumptions: first the relative speed of the random walk
of CTL in the lung vs the speed of circulation, and second, the initial size of the
infected region and its rate of growth.

4.7.3

Conclusions

Together, the ODE and ABM allow us to quantify the value of an information signal
in biologically relevant terms. The local inflammation signal in the capillary allows
search to be faster because it allows CTLs to recirculate when they arrive in capillaries in uninflamed regions of the lung. Because the lung surface area is so large,
and CTL that have exited capillaries move so slowly relative to circulating CTL, this
information signal drastically changes the ability of CTL to search the lung quickly.
It allows CTL to effectively search the large surface area of the lung in the relatively
fast flow of the blood circulatory system, and to exit only very near the site of infection. Further, because the human lung is 10,000 times larger than the mouse lung,
the search for an initially small site of infection is much more difficult. This work
shows that the effect of the local inflammatory signal is much larger in the search
for influenza in the human lung vs the mouse lung. This suggests that the role of
inflammation, chemokines and other immune signals may be different in humans and
mice. Understanding these differences is important because so much knowledge of
immunology and vaccine design depends on experimental work in mouse models.
The implications of this work extend beyond CTL search for influenza in the lung.
An effective immune response often requires finding rare localized sites of infection.
Models can make important contributions to our understanding of immune function
by explaining how the multitude of immune signaling mechanisms improve such
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search processes.
By understanding the role of information signals in the immune system we can
build models that allow us to understand how immune systems form distributed
information exchange networks to search, adapt and respond to infections. Without
central control, the interactions among millions of communicating components enable
immune systems to search and respond to complex, dynamic landscapes effectively.
We hypothesize that ant colonies, immune systems and other complex biological
systems use common informational strategies to allocate components effectively to
tasks and direct their search in space [57].
Our approach may be useful for developing decentralized search in Artificial Immune Systems [54, 26]. We anticipate that a quantitative characterization of information flow and its effect on performance will help us understand why systems of
different sizes and in different environments use different information, organizational
structures and strategies to accomplish similar tasks.
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Chapter 5
Estimating Biologically Relevant
Parameters under Uncertainty for
Within-Host West Nile Virus
Infection

5.1

Abstract

West Nile virus (WNV) is a neurotropic flavivirus that has emerged globally as a significant cause of viral encephalitis. Currently, little is known about the within host
viral kinetics of WNV during infection. We used a series of increasingly complex
mathematical models to examine WNV dynamics in mice. To the best of our knowledge, this is the first effort to model within-host dynamics of WNV. The novelty
of our approach lies in combining viremia measurements for knockout and wildtype
mice by fitting a target cell limited model to knockout mice and adaptive immune
response model to wildtype mice. This approach reduces the number of parame-
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ters that need to be estimated by the immune response model and leads to tighter
bounds on model predictions. Despite large uncertainty in model parameters, our
analysis yields tight estimates of a variety of biologically relevant quantities that are
composed of non-linear combinations of model parameters, e.g. the within-host basic
reproductive number, R0 , is between 1.7 to 7.1, the infectious virion burst size or
the average number of infectious virions released over the lifespan of a productively
infected cell is between 1.8 to 12.8 plaque forming units, and the number of cells infected per infectious virion is approximately 0.9. Previous studies have demonstrated
the critical role played by the humoral immune response in conferring protection in
WNV infected hosts by reducing the peak viral load in blood. Not only is peak viral
load an important determinant of the outcome of the infected individual, it is also
a key determinant of transmission to mosquito vectors and epidemic spread. The
models presented here are a first step in gaining a quantitative understanding of the
role of the humoral immune response in reducing host infectivity and consequently
the epidemic spread of WNV. This chapter was co-authored by Jeremie Guedj, Ruy
Ribeiro, Melanie Moses and Alan S. Perelson and is being prepared for submission.

5.2

Introduction

West Nile virus (WNV) is a flavivirus that has emerged globally as a significant
cause of viral encephalitis. It is maintained in an enzootic cycle between mosquitoes
and birds [21] but can also infect and cause disease in horses and other vertebrates
including humans. Infection of humans is associated with febrility that can progress
to lethal encephalitis [66, 67, 68]. Following its introduction into the United States
in 1999, WNV rapidly spread across North America, and more recently WNV has
been reported in Mexico, South America, and the Caribbean [22, 23, 24]. Between
1999 and 2010, there were a total of 1.8 million illnesses in humans of which 1308
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resulted in deaths [69]. Although vaccines are available for animal use, no vaccines
or specific therapies for WNV are currently approved for humans [25].
WNV is an enveloped virus with a single-stranded, positive sense, 11-kb RNA
genome [25]. Since it was first isolated in 1937 [70], substantial attention has been
given to its structure, its genome, the mechanisms of viral entry and dissemination,
the immune response it elicits and its epidemiology (reviewed in [25]). However,
information regarding the kinetics of WNV infection is limited. WNV is cytopathic
and initially infects epidermal Langerhans cells, which then migrate to the draining
lymph node where macrophages are infected [25]. From the draining lymph node,
WNV spreads to the spleen, kidney, and spinal cord and ultimately breaches the
blood-brain barrier to infect neurons [25].
Viral titers in serum indicate that the peak of virus replication occurs before the
virus has spread to the spleen and kidneys (analysis of data from [71]). Hence virus
growth until the peak appears to be mostly driven by replication in Langerhans cells
and macrophages [72]. The kinetics of WNV infection in mice is characterized by
an initial exponential growth of serum virus that peaks at 3 to 4 days post infection
(DPI), followed by an exponential decline that leads to undetectable levels of virus
by 6 to 8 DPI.
Both T and B cell responses are important in controlling WNV infection [71, 73,
25]. Viral specific immunoglobulin M (IgM) is detected just before the virus titer
peak, approximately 3 to 4 DPI, and immunoglobulin G (IgG) is detected around 8
DPI [71]. The effect of induced IgM is to lower peak viremia and reduce the time
to peak viremia [71]. A cytotoxic T cell response does not appear until 6 DPI, well
after the peak of virus replication[74]. Our goal is to quantitatively describe the
interplay between viral dynamics and the immune response in the early phase of
WNV infection.
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Mathematical models have proven to be useful tools in the analysis of viral infections. For example, the dynamics of human immunodeficiency virus (HIV) infection
were poorly understood until mathematical models were developed. These models
were used to analyze the kinetics of viral load decline in patients under therapy and
were able to estimate the rate of HIV replication, the number of virus particles produced and cleared daily, and the average life span of infected cells[75, 76, 77, 78].
Similar models have been used to analyze the effects of interferon and ribavirin on
hepatitis C virus (HCV) dynamics [79, 80, 81] as well as the effect of drugs on hepatitis B virus (HBV) kinetics [82, 83, 84]. These models took advantage of the fact that
HIV, HCV and HBV infection produce prolonged chronic diseases where the virus
population attains steady state. Perturbation of the steady state by drug administration helped to reveal the underlying kinetics of viral production and clearance.
In contrast, WNV produces an acute infection of short duration. Previous work has
applied modeling strategies to understand the kinetics of acute infection in influenza
[85, 86, 87]. To date there are no within host models of WNV infection.
Here, based on data obtained during experimental infection of mice, we develop
kinetic models of WNV infection. We proceed systematically to estimate rates of viral
replication, innate immunity and adaptive immune response. We first use empirical
data to estimate a parameter characterizing the rate of clearance of WNV by innate
immune responses in the first 90 minutes of infection. Next, we analyze data from
a knockout experiment in which there was no humoral (IgM) response in order to
characterize WNV infection dynamics in the absence of the initial adaptive response.
Then we incorporate these parameters into a model to characterize the kinetics of the
humoral response from experimental data in wild type mice. Using this approach
we estimate some parameters in isolation, and then incorporate those parameters
into a more complex model that includes an adaptive immune response. Thus, we
avoid the problem of needing to fit more parameters in our final model than can be
identified from the data.

71

Chapter 5. Quantifying Uncertainty in Kinetics of Within-Host WNV

We use a computationally intensive method to estimate ranges of parameters
that could possibly have generated the observed viremia curves. The problem is
computationally challenging since the potential parameter space is very large and
tradeoffs between model parameters complicate parameter estimation. We reduce the
parameter space that needs to be explored by imposing constraints from experimental
data. Our computational framework incorporates the large uncertainties in imposed
bounds on model parameters. We then explore this space by parameterizing our
models with millions of feasible parameter combinations, and comparing the resulting
predicted viremia curves to empirical data.

5.3
5.3.1

Materials and Methods
Study data

The data examined here came from three experimental infection studies of WNV[71,
73, 4]. In order to estimate the infectious viral decay rate, we use a viral decay
study which intravenously inoculated wild type (C57BL/6) mice with 105 plaque
forming units (PFU) of WNV 3356 NY2000 [4]. Serum was collected 5 mins, 15
mins, 45 mins and 90 mins post infection. Blood samples were centrifuged at 8,000
rpm for 5 min, and serum was collected and frozen at -80◦ C until tested for virus by
plaque assay on Vero cells.
The second set of studies (wildtype and knockout mouse studies) were based
on experimental infections of wildtype and IgM knockout mice. In these studies, wild
type and knockout (sIgM−/− C57BL/6J) mice were subcutaneously inoculated with
100 PFU of a strain closely related to the one used in the viral decay study (WNV
3000.0259 NY2000) [71]. Serum was collected every other day until 10 DPI and
titrated for virus by plaque assay on BHK-21 cells. The wildtype and knockout
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mouse study measured viremia in terms of both viral RNA and PFU but the latter
had fewer measurements. Since the viral decay study measured infectious virus
(PFU), we converted all RNA measurements in the wildtype and knockout mouse
study to PFU. We calculated the ratio of RNA copies per mL of blood for knockout
mice to the viral titer in PFU per mL of blood for knockout mice at day 2 and 4 post
infection from the experimental data. For WNV, we found that approximately 500
RNA copies on average corresponded to an infectious unit (PFU). Hence we scaled
the viral measurements for wildtype mice, originally measured in RNA copies per
mL of serum, to account for the fact that not all viral particles produce infections.
Finally, in order to determine the effect of the antibody response, we used an
antibody titer study that subcutaneously inoculated wildtype (C57BL/6J) mice
with 100 PFU of WNV 3000.0259 NY2000 [73]. Serum was collected every other day
until 12 DPI and neutralizing antibody titers were determined by a standard plaque
reduction neutralization assay [88]. The amount of antibody (measured in units of
plaque reduction neutralization titer for 50% inhibition, PRNT50 ) was determined.

5.3.2

Fitting models to data

The ordinary differential equations describing our viral kinetic models (Eqs. 5.1 5.4 and Eqs. 5.7 - 5.11) were solved numerically in Matlab [31]. The Runge-Kutta
4 method of integration was employed with a step size of 0.0004. The curve-fitting
method uses nonlinear least-squares regression that minimizes the sum of the squared
residuals between the experimental and predicted values of log10 PFU/mL of serum.
We weighed all the data points equally in our fitting procedure since no uncertainty
was provided for the experimental viral titers.
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Figure 5.1: Equation 5.5 fit to data from the viral decay study [4] where viral titers in
serum were measured within the first 90 minutes following intravenous inoculation of
mice with WNV. Best fit using linear least-squares regression (r2 = 0.85 and p-value
= 2 × 10−5 ).

5.3.3

A target cell limited model

We first analyze WNV dynamics in immunodeficient (IgM knockout) mice incapable
of antibody response. We assume that the infection is target-cell limited in these
mice, i.e. the concentration of virus reaches a peak and then declines when few
susceptible target cells remain. Models of target cell limited acute infection have
been developed for both HIV [92] and influenza A virus infection [85]. Here we use
a target cell limited model with an eclipse phase, given by the following differential
equations:

dT
= −βT V
dt
dI1
= βT V − kI1
dt

(5.1)
(5.2)
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Table 5.1: Input parameters to model
Parameters Description

Estimated Ranges

Source

γ

WNV clearance ≤ 44.4/day (95% confidence in- Fit to viral derate
terval 29.5 - 54) also varied cay study [4]
with values 10/day, 20/day and
44.4/day

t1/2
(= ln2/γ)

Half-life of free ≥ 22.5 minutes (95% confidence Calculated
virus
interval 18.5 - 33.8)

η

Rate of IgM pro- 54.7/day
duction

Fit to antibody
titer study [73]

T0

Initial target cell 2.2 × 104 - 2.4 × 106 /mL
density

Estimated from
[89]

k

Rate of transi- 2.4 - 4/day
tion from I1 to I2

Estimated from
[90, 91]

dI2
= kI1 − δI2
dt
dV
= pI2 − γV − βT V
dt

(5.3)
(5.4)

where T is the number of uninfected target cells, I2 is the number of productively
infected cells, and V is the viral titer in serum. Target cells become infected by virus
at rate βT V , where β is the rate constant characterizing infection. The initial viral
titer and the initial number of target cells are denoted V0 and T0 , respectively. The
initial number of infected cells is assumed to be zero. The separation of infected
cells into two classes, I1 cells that are infected but not yet producing virus and I2
cells that produce virus, is similar to that in a model proposed earlier for influenza
infection [85]. This separation increases the realism of the model, since delays in the
production of virus after the time of initial infection are part of the viral life cycle

75

Chapter 5. Quantifying Uncertainty in Kinetics of Within-Host WNV

(the eclipse phase).
The parameter 1/k is the average transition time from I1 to I2 . Productively
infected cells (I2 ) release virus at an average rate p per cell and die at rate δ per
cell, where 1/δ is the average life span of a productively infected cell. Free infectious
virus is cleared at rate γ per infectious unit per day, for example by phagocytosis
or loss of infectivity and is lost by entering cells during the infection process at rate
βT V . The effects of innate immune responses and T cell responses are not explicitly
described in this model, but are implicitly included in the clearance rate of virus
(γ) and the death rate of infected cells (δ). Since virus requires some time to infect
cells, produce progeny, and lead to the death of infected cells, immediately after
intravenous inoculation virus titers decline because virus is not yet being produced
but is still being cleared as described by

dV
= −(γ + βT0 )V
dt

(5.5)

where T0 is the density of infectible target cells in blood and β is the infection rate
constant of WNV for such target cells. Thus immediately after infection we expect
an exponential decline in viral titer with rate γ + βT0 . Viral titers in serum within
the first 90 minutes following intravenous inoculation of mice with 105 PFU of WNV
were reported in Fig. 7 of ref. [4] (viral decay study). Using this data, we estimate
γ + βT0 = 44.4/day (Fig. 5.1). Thus γ ≤ 44.4/day and the half-life of free virus
(t1/2 = ln2/γ) is ≥ 22 minutes.
Since the viral decay study used intravenous inoculation and measured viremia
in blood until 90 minutes post infection, the infectible cell types are different from
a study that uses a footpad inoculation route. It is also difficult to estimate what
proportion of virus gets into organs and lymph nodes and the proportion of all
infectible cells that are reached in the first 90 minutes after inoculation. Hence the
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target cell density for intravenous inoculation (T0 ) in the viral decay study is probably
different from the target cell density for footpad inoculation in the wildtype and
knockout mice (T0 ). Since the rate constant of infection depends on the infectible
cell types, the corresponding rate constants of infection (β and β) are also probably
different in the two settings. Since we are unaware of any data that would allow us to
independently estimate βT0 , we fixed γ at various values ≤ 44.4/day and examined
the sensitivity of our estimates of other model parameters to this choice. We also
iterated through values of the eclipse phase duration (1/k) ranging from 6 hours to
10 hours and varied 1/δ from 1 hour to 72 hours (see 5.3.6 Biological constraints on
model parameters).
For biologically feasible combinations of parameters, we generate a viremia curve,
and compare it to empirical data from the knockout mice study [71] in order to
identify a set of the target cell limited model parameters (V0 , β, p and δ) that could
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Figure 5.2: Model fit to data from wildtype and knockout study using one representative best-fit parameter estimate. The solid line is the target cell limited model
fit to data (squares) from knockout mice. The dotted line is the model including a
humoral response fit to data (circles) for wild type mice.
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Figure 5.3: Fit of the function A(t) given by Eq. 5.6 to the neutralizing antibody
data (circles) from the antibody titer study.

5.3.4

Model incorporating an adaptive immune response

Humoral immunity is an essential component of the immune response to WNV,
as neutralizing antibodies limit dissemination of infection [71, 73]. Diamond et al.
[73] (antibody titer study) infected wild type mice subcutaneously with WNV and
measured titers of neutralizing antibody as shown in Fig. 5.3. The data can be
described by the following piecewise linear function:

A(t) =




0 , t < ti

(5.6)

 η(t − ti ) , t ≥ ti
The level of neutralizing antibody at time t, A(t), measured by the plaque reduction neutralization test (PRNT) is 0 before time ti and increases linearly with time
after that with rate η. This equation was fit to the antibody titer data (Fig. 5.3)
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and η and ti were estimated (Table 5.1).
The target cell limited model given by Eqs. 5.1-5.4 can be generalized to include
neutralizing antibody. We assume that neutralizing antibody, A, binds virus, V , and
neutralizes it with rate constant ρ, so that infectious virus is lost at rate ρA(t)V . The
model including neutralizing antibody consists of the following differential equations:

dT
= −βT V
dt

(5.7)

dI1
= βT V − kI1
dt
dI2
= kI1 − δI2
dt
dV
= pI2 − γV − βT V − ρA(t)V
dt


0 , t < ti
A(t) =
 η(t − ti ) , t ≥ ti

(5.8)
(5.9)
(5.10)

(5.11)

Note that Eqs. 5.7-5.9 are the same as Eqs. 5.1-5.3. This model has many more
parameters than we can estimate reliably from experimental data in wildtype mice.
The basic target cell limited model (Eq. 5.1 - 5.4) has fewer parameters but is not
biologically realistic for wildtype mice. Both models can fit the experimental dataset
equally well. In order to reliably estimate parameters, we used a target cell limited
model to analyze data from knockout mice (knockout study, [71]) in which there is
no humoral response. This allowed us to estimate key parameters in a target cell
limited model related to WNV replication in the absence of a humoral response.
Then we applied the model incorporating a humoral immune response to analyze
data obtained from wildtype mice (wildtype study, [71]), while fixing the parameters obtained from the fits to the knockout mice. This leaves fewer parameters to
estimate in the model with an adaptive immune response. This unique combination
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of knockout experimental data and models allows us to reliably estimate parameters
for the more complex adaptive immune response model.
For the model with a humoral response, we estimated the parameters V0 , ρ and
ti . We re-estimated V0 in this model because a different experiment was analyzed.

5.3.5

Estimation of initial target cell density (T0 )

Subcutaneously inoculated WNV initially infects Langerhans cells [93] and
keratinocytes [94] in skin. Langerhans cells then migrate to the draining lymph
node and lead to infection of cells that have not been definitely identified but are
thought to be macrophages and follicular dendritic cells [93]. A study silencing early
viral replication in dendritic cells and macrophages showed suppression of WNV
replication [72] suggesting that these two populations are the major target cells for
WNV.
We obtain a rough estimate of the initial density of target cells (T0 ) based on
several dendritic cell types. We found estimates for the number of different dendritic
cell subsets (CD8− , CD8+ and CD8int ) 1 day after infection with mouse mammary
tumor virus to be approximately 3000 in the draining popliteal lymph node [89]. Here
we assume that WNV infection will lead to a similar density of lymph node dendritic
cells. In order to account for other subsets of dendritic cells and macrophages, we
set the number of a target cells to a value an order of magnitude higher than this
(30,000). We estimate the density of target cells by multiplying the number of target
cells by 22, the estimated number of lymph nodes in mice [95] and then dividing
it by the total blood volume which is approximately 3 mL (the blood volume in
mice is approximately 95 mL/kg of body weight [96] and the weight of C57BL/6J
mice is approximately 30 grams [97]). This gives us an initial target cell density of
T0 = 2.3 × 105 /mL. Given the uncertainty in this estimate, in our analysis we vary
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T0 by an order of magnitude above and below this value.

5.3.6

Biological constraints on model parameters

In order to reduce the parameter space that needs to be explored we constrained
the range of various parameters based on experimental data. We constrained the
duration of the eclipse phase (1/k) and the duration of productive infection of an
infected cell (1/δ) in the following manner. The duration of the eclipse phase for
neuronal cells infected in-vitro with WNV is 6 to 8 hours [91]. Experimental data invivo suggests that WNV completes one round of replication in dendritic cells within
12 hours in mice [90]. Hence the duration of the eclipse phase in-vivo is less than 12
hours in mice. We constrained the eclipse phase to be between 6 hours and 10 hours.
WNV infection can cause both cytolysis and profuse budding in infected cells
[98]. Hence infected cells may continue to produce virus (due to viral budding) even
after the first round of WNV replication. In order to simulate this, we set the upper
bound on the productive lifespan of an infected cell (1/δ) to 3 days. We also fixed
the minimum productive lifespan of an infected cell in a model with an eclipse phase
(1/δ) to be 1 hour.
Bounds on the initial density of inoculated virus (V0 ) were set in the following
manner. The wildtype and knockout mice study inoculated 100 PFU of WNV into
the mouse footpad. Assuming complete absorption into blood (3mL in mice) gives
an upper bound for V0 of approximately 33.3 PFU/mL. For the lower bound, we
assume 1% absorption into whole tissue (30 mL in mice) and obtain approximately
0.01 PFU/mL.
Finally, the time of initiation of the IgM response (ti ) was constrained from the
antibody titer study [73]. The study measured antibody titers on alternate days
post infection and the first measurable antibody titer occurred at 4 DPI. Hence we
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constrained ti to be between 2 to 4 days.
Target cell limited model
Iterate through T0 , k, γ

Generate random
parameters

γ ≤ 44.4/day (viral decay study)
2.2 ×10 4 /mL ≤ T0 ≤ 2.4 ×10 6 /mL

Uniformly sample V0 , β, p, δ

V , β , pi , δ i
i
0

2.4/day ≤ k ≤ 4/day
0.01 PFU/mL ≤ V0 ≤ 33.3 PFU/mL

i

∀i 1≤ i ≤ 630, 000

Step 1

reﬁneparameters

4/day ≤ δ ≤ 24/day
Knockout mice data

T0j , k j ,V0j , β j , p j , δ j , γ j

∀j 1≤ j ≤ 59,520 s.t. SSR < 4

Adaptive response model
reﬁneparameters

0.0

FU/mL ≤ V0 ≤ 33.3 PFU/mL

2 days ≤ ti ≤ 4 days

η = 54.7 (antibody titre study)
Wildtype mice data

ρ, ti

Step 2

Re-estimate V0

T0j , k j ,V0j , β j , p j , δ j , γ j

∀j 1 ≤ j ≤ 59, 520
Step 3

reﬁneparameters

T0l , k l ,V0l , β l , pl , δ l , γ l , l , til

∀l 1 ≤ l ≤ 690, 000 s.t. SSR < 0.1

Figure 5.4: Outline of the computational approach.

5.3.7

Computational Approach

We set up a framework to explore the biologically plausible parameter space. We use
a computationally intensive method to sample feasible combinations of parameters
from which we generate viremia curves. We compare each curve to empirical data in
order to identify a set of parameters that could have generated the empirical data.
We are interested in determining the plausible range of biological parameters
and not the single set of parameters that give the best fit. Hence we do not use
optimization techniques like genetic algorithms [65] but instead generate samples
uniformly at random from the intervals imposed from biology. Each of these samples
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was given as input to a subroutine we developed, refineparameters, which was used
to search for parameter sets that produce viremia curves consistent with observed
data. The subroutine (written in Matlab [31]) creates a search grid consisting of
new guesses for model parameters centered around the initial guesses it takes as
input. Each grid cell represents an initial guess which was used as input to a Matlab
optimization function (lsqcurvefit). The grid was created by varying the guessed
model parameters by a specified percentage either on the log scale or numerical scale
and then combining each parameter combination with all other possible combinations
of the remaining parameters. It then searched for combinations of input model
parameters that generate viremia curves consistent with observed data by calling the
Matlab optimization routine lsqcurvefit on each initial guess for model parameters
represented by a grid cell. The subroutine imposes biological constraints on model
parameters (described in Section 5.3.6, Biological constraints on model parameters).
The computational approach is outlined in Figure 5.4. The steps of the method are:
Step 1: Iterating through values of T0 , k and γ and generating random
guesses for V0 , β, p and δ. We iterated through specific values of T0 , k and γ in
order to determine how those parameters affect the parameters we are interested in
predicting. We varied T0 from 2.2 × 104 /mL to 2.4 × 106 /mL. We varied the duration
of the eclipse phase (1/k) from 6 to 10 hours, and we varied the viral clearance rate
(γ) from 10/day to 44.4/day (Table 5.1). For each of seven values of T0 , three
values of k, and three values of γ, we generated guesses uniformly at random for the
parameters (V0 , β, p, δ) within their biologically realistic ranges. We divided each
parameter into 10 intervals on the log scale, and generated 10 random guesses within
those intervals. Each parameter value was then combined with all combinations of
the remaining parameters to generate 104 random guesses for the parameters (V0 ,
β, p, δ) for each value of T0 , k and γ, giving a total of 7 × 3 × 3 × 104 = 630, 000
random guesses. These random initial guesses were then provided to the subroutine
refineparameters, that searched for parameter sets (V0 , β, p, δ) that produce viremia
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curves consistent with observed data. We retained all solutions that yielded a sum
of squared residual less than a threshold (4[log10 PFU/mL]2 ) that was chosen to give
visually good fits (59,520 solutions). These sets of solutions that yielded good fits to
the knockout mice data were then sent as input to Step 2.
Step 2: Re-estimating V0 for the immune response model. The sets of
model parameters (V0 , β, p, δ) (59,520 solutions) estimated for the target cell limited
model were then used to estimate a corresponding set of parameters (V0 , ρ, ti ) for
the immune system model. For each set of model parameter estimates (β, p, δ) from
the target cell limited model, the parameter V0 was re-estimated for the immune
response model since the day 2 viremia for wildtype mice was lower than the day 2
viremia for knockouts. The subroutine refineparameters was given the list of 59,520
solutions (V0 , β, p, δ) from Step 1. The search grid was created by varying the values
of V0 from the target cell limited model by ± 50% on the log scale with 30 samples.
We took the best value of V0 (V0 ) for a given combination (β, p, δ). The final output
from this step is a new list of solutions (V0 , β, p, δ). This gave a new set of 59,520
combinations of (V0 , β, p, δ) where only V0 is re-estimated. These solutions are the
input to Step 3.
Step 3: Estimating immune response parameters ρ and ti . In this step,
for each set of model parameter estimates (V0 , β, p, δ) from the output list of Step 2
(59,520 solutions), the immune response parameters (ρ, ti ) were estimated by a new
call to refineparameters.
The subroutine refineparameters was given the list of all solutions (V0 , β, p, δ)
from Step 2. The search grid was created by varying ρ and ti uniformly along the
−1
constraints (ρ varying from 0 − 50PRNT−1
50 day and ti trying from 2 - 4 days) and

then combining each combination of ρ (25 values) with all other possible combinations
of ti (9 values). The bound on ρ was found to be sufficient since ρ co-varied with
model parameters like δ on which we had good biological constraints.
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From the list of 25 × 9 × 59, 520 = 13, 392, 000 solutions, we retained all solutions
that yielded a sum of squared residual less than a threshold (0.1[log10 PFU/mL]2 )
that was chosen to give visually good fits. This threshold is lower than the one
for the target cell limited model since there are fewer data points available for the
wildtype study. These sets of solutions that yielded good fits to data were then used
to calculate ranges of model parameters for the immune system model (wildtype
mice) (Tables 1 and 2). The final output of this step is a set of combinations of
(V0 , β, p, δ, ρ, ti ) filtered by a threshold of sum of squared residuals. These sets of
solutions that yielded good fits to data were then used to calculate ranges of model
parameters for the knockout mice and wildtype mice (Tables 5.1 and 5.2). The
computational approach is outlined in Figure 5.4.

5.4
5.4.1

Results
Target cell limited model

The estimated ranges of model parameters are shown in Tables 5.1 and 5.2. The
model fit to the data using one representative best-fit parameter estimate is shown in
the solid line in Fig. 5.2. The ranges of model parameters generated after varying T0
an order of magnitude above and below the default value (2.3 × 105 /mL) and varying
1/k from 6 to 10 hours are reported in Tables 5.1 and 5.2, and the histograms of the
estimated model parameters are shown in Fig. 5.6.
Despite considerable uncertainty in imposed bounds on model parameters (the
initial target cell density, T0 , is allowed to vary by two orders of magnitude), we are
still able to calculate biologically relevant quantities with tight bounds. The infectious virion burst size (p/δ) or the average number of infectious virions released over
the lifespan of a productively infected cell was estimated to be between 1.8 and 12.8
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Figure 5.5: Histograms of biologically relevant quantities estimated by our approach.
Top Left - Infectious virion burst size (in PFU). Top Right - Average number of cells
infected per infectious virion. Bottom - Basic reproductive number (R0 ).

PFU. Since we estimated the ratio of WNV RNA copies to PFU to be approximately
500, this implies that on average an infected cell produces approximately 900 to 6400
RNA copies over its productively infected lifetime. We also estimated the average
number of cells infected by an infectious virion (βT0 /(γ +β ·T0 )) to be approximately
0.9. Even though our model parameter estimates (like the productively infected cell
lifetime, 1/δ) are no tighter than the imposed biological constraints, we are still able
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target cell limited model and model with humoral response.

to predict biologically relevant quantities with reasonable precision.

We also estimated the basic reproductive number (R0 ). This number represents
the average number of second generation infections produced by a single infected cell
placed in a population of susceptible cells. If R0 is greater than 1, then an infection
can be established, whereas an infection rapidly dies out if R0 is less than 1. For the
target cell limited model (Eqs. 5.1-5.4), R0 is given by [99]:
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R0 =

pβT0
δ(γ + β · T0 )

(5.12)

Using Eq. 5.12 we estimated the value of R0 to be between 1.7 and 7.1 with an
average of 2.5 (Table 5.2).
Despite considerable variation in individual model parameters, the estimates of
the biologically relevant quantities like the basic reproductive number, burst size and
number of cells infected by an infectious virion are tightly bound (Fig. 5.5). These
biologically relevant quantities are combinations of model parameters. Fitting the
model to data reveals correlations between model parameters (Fig. 5.7). Without
the fitting of models to data and with the imposed biological constraints, we would
expect the basic reproductive number to vary from 1 to 30 (variation with fitting is
1.7 to 7.1) (Fig. 5.5). Similarly we would expect the infectious virion burst size to
vary from 1 to 30 PFU (variation with fitting is 1.8 to 12.8 PFU) (Fig. 5.5).
We observed that model parameters had tradeoffs with each other (Fig. 5.7). This
precluded estimation of unique values for the model parameters. However this also
helped us to constrain additional model parameters, since they depend on parameters
that we could put experimental bounds on. For example, the rate constant for
infection β, for which we have no experimental bounds, has a statistically significant
relationship with the initial density of inoculated virus, V0 (Fig. 5.7, p-value < 0.001,
r2 = 0.12). The experimental bounds on V0 constrain feasible values of β.
Additionally, the virus production rate, p, has a statistically significant relationship with the productively infected cell death rate, δ (Fig. 5.7, p-value = 0, r2 =
0.27). Such tradeoffs preclude estimation of unique model parameter values and imply that there is a family of solutions. The estimated ranges of model parameters in
conjunction with the correlation plots between model parameters define the family
of solutions that have good fits to data.
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Table 5.2: Imposed biological constraints and estimated output ranges, mean and
standard deviation of model parameters
Statistic
Bound
Range
Mean
SD

V0
[0.01,
33.3]
[0.01,
33.3]
5.2
4

β
[10−5 , 10−2 ]

δ
[0.3, 24]

p
[0.3, 120]

ρ
[1, 50]

ti
[2, 4]

R0
[1, 30]

p/δ
[1, 30]

[2 × 10−4 ,
9 × 10−2 ]
1.5 × 10−3
2

[1.7, 24]

[5.2,
118.2]
28.1
1.8

[1, 50]

[2, 4]

22.7
15

2.9
0.4

[1.7,
7.1]
2.5
0.4

[1.8,
12.8]
3
1

9.9
2

where bounds are the imposed biological constraints, range is the minimum and
maximum estimated value, mean and SD (standard deviation) are of parameter
estimates, V0 is the inoculated virus density (PFU/mL), β is the rate constant of
infection [(PFU/mL)−1 day−1 ], δ is the death rate of productively infected cells (day−1 ), p
is the virus production rate (PFU/mL), ρ is the efficacy of antibody neutralization
−1
(PRNT−1
50 day ), ti is the time of initiation of IgM response (days post infection), R0 is
the basic reproductive number (Eq. 5.12) and p/δ is the infectious burst size (average
number of virus particles produced over the lifetime of an infected cell, PFU)
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5.4.2

Model incorporating an adaptive immune response

The model with an adaptive antibody response has two additional parameters, ρ
−1
(efficacy of adaptive IgM neutralization, PRNT−1
50 day ) and ti (the time of initiation

of the adaptive IgM response, days). The initial density of inoculated virus, V0 , is
also re-estimated. The best-fit ranges of these parameters are given in Table 5.2. The
model fit to the data using one representative best-fit parameter estimate is shown
by the dotted line in Fig. 5.2.

5.4.3

Caveats and Limitations

Our adaptive immune response model combines data from two different strains of
mice (both conducted in the Diamond lab under the same experimental conditions).
We assume that the parameters β, p, δ estimated from the target cell model are
unchanged in the wild type mice with an IgM immune response. All variation in
viremia prior to the peak is attributed to differences in the inoculated dose (V0 ).
Additionally, combining data from the two mice strain studies required us to convert
the RNA measure from the wildtype and knockout study [71] into a PFU measure
used in the viral decay study [4] (detailed in Study Data).
We also eliminate parameter values that generate viremia curves with sum of
squared residuals above a threshold. Our thresholds are chosen based on visual fit,
which is subjective. Finally, in our calculation of biological bounds on productively
infected cell lifetimes, we assume that WNV is cytopathic in-vivo and that an infected
cell is lysed after WNV completes one round of replication. WNV has been shown
to be cytopathic in-vitro in K562, Neuro 2a [100] and neuronal cells [101]. However
WNV infection in-vitro is cytopathic only at low infectious doses in another cell line
(Vero cells) [98].
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5.5

Discussion

Here we describe a method to predict biologically relevant quantities for WNV while
having large uncertainty in biological bounds imposed on model parameters. We use
a novel approach to combine knockout experimental data and mathematical models.
A humoral immune response contributes to the successful clearing of WNV infection
[71]. However a mathematical model incorporating a humoral response has many
more parameters than we can estimate reliably from the available experimental data
in wildtype mice. A basic target cell limited model has fewer parameters but fails to
capture a progressively increasing rate of virus clearance due to a humoral response.
Both models can fit the experimental dataset equally well. In order to reliably
estimate parameters, we first analyzed data from knockout mice (using a target cell
limited model) in which there is no anti-WNV IgM response, and hence no IgMIgG switch to produce a primary IgG response [35]. This allowed us to estimate
key parameters in a target cell limited model related to pathogen replication in
the absence of a humoral response. Then we applied a more sophisticated model
incorporating a humoral immune response to analyze data from wildtype mice while
fixing the parameters obtained from the fits to the knockout mice. This allowed us
to estimate (fewer) parameters related to the adaptive immune response. Hence this
unique combination of knockout experimental data and models allows us to reliably
estimate model parameters.
We then set up a framework to explore large parameter spaces after imposing
constraints from biology. There is considerable variation in model parameters even
after imposing biological constraints, e.g. the initial density of target cells, T0 , is allowed to vary by two orders of magnitude. The optimization routine, which generates
best-fit model parameters, is sensitive to the initial guesses for parameters provided
to it. Hence we sample model parameters (V0 , β, p and δ) uniformly at random from
the imposed biological ranges and these randomly generated parameters are used as
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initial guesses for the optimization routine. Finally we select those model parameters
that give predictions consistent with our goodness of fit threshold. The problem of
estimating the ranges of model parameters is computationally challenging since this
requires solving differential equations millions of times. Such computationally hard
problems have been solved using other approaches in other diseases [102, 103, 104].
Despite considerable variation in model parameters (the initial target cell density, T0 , is varied by two orders of magnitude), we are able to calculate biologically
relevant quantities with tight bounds. We calculated the basic reproductive number,
R0 , which indicated that a single infected cell produces between 1.7 to 7.1 new infections. The infectious virion burst size (p/δ) or the average number of infectious
virions released over the lifespan of a productively infected cell was estimated to be
between 1.8 and 12.8 PFU. Since we estimated the ratio of WNV RNA copies to
PFU to be approximately 500, this implies that on average a productively infected
cell produces approximately 900 to 6400 RNA copies over its productively infected
lifetime. Finally, we also estimated the average number of target cells infected by
an infectious virion (βT0 /(γ + β · T0 )) to be approximately 0.9. Even though our
individual model parameter estimates (like the productively infected cell lifetime,
1/δ) are no tighter than the imposed biological constraints, we are able to predict
biologically relevant quantities with reasonable precision.
How are we able to predict biologically relevant quantities with certainty even
though there is uncertainty around model input parameters? Fitting the model to
data produces combinations of parameters that can explain the data. The fitting
process eliminates combinations of model parameters that cannot explain the data
and hence reveals correlations between estimated model parameters. The biologically
relevant quantities are combinations of model parameters. Without the fitting of
models to data and with the imposed biological constraints, we initially guessed that
the basic reproductive number, R0 , could vary from 1 to 30 (variation with fitting is
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1.7 to 7.1) and the infectious virion burst size could vary from 1 to 30 PFU (variation
with fitting is 1.8 to 12.8 PFU) (Fig. 5.5).
We examined the dependence of model parameters on each other and observed
trade offs between model parameters. (Figure 5.7). This would normally complicate
parameter estimation, but we used this to further constrain model parameters on
which we have no known constraints. For example, increasing the infectious virus
production rate (p) tended to increase the estimated productively infected cell death
rate (δ). This is not surprising since the same total count of virus production per
cell can be achieved by increasing p but having the cells live a shorter time, i.e., also
increasing δ. There are biological bounds on many of these parameters and we used
the fact that parameter estimates are correlated to constrain parameters for which
we do not have biological constraints (like the production rate p). In the previous
example, we have good bounds on δ and since p and δ are correlated, we could put
bounds on p also.
Our method of estimating biologically relevant quantities despite uncertainty in
imposed bounds on model parameters could be more generally applicable to modeling
of other diseases where it is difficult to impose tight biological bounds on parameters.
We may be able to predict biologically relevant quantities for other pathogens with
a lot more certainty than individual model parameters. The process of fitting models to data should reveal parameter correlations. Such correlations between model
parameters help our computational framework find tighter constraints within the
imposed biological bounds.
Our modeling makes suggestions for further experimental work. More frequent
measurement of viremia and in-vitro measurements of infectious virus decay and
the viral production rate would give more accurate parameter estimates. In-vitro
experiments where the initial target cell density, T0 , can be accurately measured
would help in getting precise estimates of parameters that vary with it, like the
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infected cell death rate, δ (Figure 5.7).
The humoral immune response has a critical role in conferring protection in WNV
infected hosts [71]. It reduces the peak viral concentration in blood as well as the
time taken to reach peak viremia. Peak viremia is an important epidemiological
determinant for the spread of WNV [5], which is mosquito vector borne. Above a
threshold peak viremia of 105 PFU/mL of blood, a host is capable of infecting an
uninfected mosquito, which in turn can infect other uninfected hosts and maintain
WNV in an enzootic cycle [5]. Hence hosts that can sustain peak viremia above this
threshold and for a longer duration are pathogen reservoirs. As evidenced in Fig. 5.2,
in the presence of an induced IgM response the peak viremia and the time to peak
viremia are both reduced compared with the kinetics seen in the IgM deficient mice.
The models presented here are a first step towards a quantitative understanding of
the role of the humoral immune response in reducing host infectivity and the epidemic
spread of WNV.
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Chapter 6
A Proof of Concept for
Multi-Level Hierarchical Bayesian
Estimates of Within-Host Viral
Dynamics

6.1

Introduction

Multilevel models like hierarchical Bayesian models reduce estimation error when
they are informed by group level knowledge [13]. Hierarchical Bayesian models take
between and within subject variation into account simultaneously. These models pool
information across disparate individuals from different groups and are well suited for
cases where there are a limited number of observations from several individuals. Hierarchical Bayesian models have been used in image processing [14], ecological modeling [15] and climate modeling [16]. Bayesian non-linear mixed effects models with a
single level of hierarchy have been applied to modeling of the within-host response to
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HIV [17, 18] and influenza [19]. However to the best of our knowledge, Bayesian nonlinear mixed effects models with multiple levels of hierarchy have not been applied to
within-host modeling. Multilevel data fitting approaches and Bayesian frameworks
are expected to be helpful to modeling within-host viral dynamics [20].
We use a multi-level hierarchical Bayesian model that has three taxonomic levels
and is a natural fit to the hierarchical structure of experimental data. Phylogeny
and life history are important determinants of the pathogenesis of WNV. Passerine species sustain more viremia than non-Passerine species [5]. Old World species
are more susceptible to WNV infection than New World species [105]. We aim to
use hierarchy to make better estimates of biologically relevant quantities for WNV.
Using a very simple model operating on simulated data, this chapter compares a
multi-level hierarchical Bayesian non-linear mixed effects model to an aggregated
Bayesian model. We compare estimates of Ordinary Differential Equation (ODE)
model parameters in hierarchical versus aggregated models.
Hierarchical Bayesian models encapsulate knowledge about the underlying biology as priors. Suitable priors in a hierarchical Bayesian framework can help reduce
variance of parameter estimates [13]. In some cases use of prior information can help
identify parameters that otherwise might be unidentifiable [18]. A model that incorporates the hierarchal nature of phylogeny, life history and mass of infected species,
and encodes this information as priors in a hierarchical Bayesian model may enable
more accurate estimates of parameters characterizing WNV infection.
Modeling of biological systems is complicated by the effects of noisy experimental
data and the difficulty of creating models that completely capture biological realism.
In order to control the effect of noisy data and model uncertainty, this chapter uses
a known model to generate simulated data with varying amounts of noise. The
hierarchical Bayesian model then incorporates known information about differences
between species as priors and then infers the model parameters. The accuracy of the
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Bayesian model can be calculated by comparing its parameter estimates to the actual
parameter values (ground truth). Given known data, this chapter focuses on the
circumstances under which a hierarchical Bayesian approach (with prior information)
can generate more accurate estimates of model parameters than simple Bayesian
models.
This chapter aims to refine and validate the hierarchical Bayesian models to be
used in the next chapter, which will use these models on actual experimental data.
The goals of this chapter are:

1. To implement a novel multi-level hierarchical Bayesian model to estimate parameters in a mathematical model of viral dynamics.

2. To outline the circumstances under which a multi-level hierarchical Bayesian
model with biologically motivated priors can generate more accurate estimates
of parameters (in a simpified viral dynamics model) than aggregated Bayesian
models without hierarchy. The models are compared based on the accuracy of
estimated parameters at different levels of the hierarchy. We use the sum of
squared residuals between model predicted values and ground truth values to
measure accuracy.

3. Provide a foundation to test model parameters characterizing WNV infection
and host immune response for dependence on host body mass. The following
chapter (Chapter 7) will use a multi-level Bayesian model to estimate parameters characterizing WNV infection from real experimental data.
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6.2

Materials and Methods

6.2.1

Overview of Methods

The Bayesian inference approach can be described as follows. Assume that a model
(in our case a differential equation model describing how virus concentration changes
over time in serum) is represented by parameters Θ. The Bayesian approach allows
us to include prior knowledge about model parameters in a systematic fashion. If
we have information about Θ (e.g., from experimental evidence) which needs to be
incorporated in our analysis, this is represented as a prior probability distribution
P (Θ). Bayes Rule allows us to incorporate the prior knowledge about parameters,
P (Θ), and experimental data, D, to derive a posterior distribution of parameters:

P (Θ|D) =

P (D|Θ) · P (Θ)
P (D)

(6.1)

The multi-level hierarchical Bayesian model mimics the hierarchical nature of
phylogeny. There are three levels in the hierarchical tree representation: individual,
species and genus (Fig. 6.3). Each level of the tree has an equation describing
the distribution of model parameters (differential equation model, Eq. 6.2). The
differential equation and hierarchical Bayesian models are explained in greater detail
in the next section.
Our goal is to compare two different hierarchical Bayesian models: a multi-level
model that has three levels of hierarchy (individual, species and genus) (Fig. 6.3) and
an aggregated model with two levels of hierarchy (all individuals of all species pooled
together under a single genus) (Fig. 6.2). We compare the accuracy of parameter
estimates with respect to ground truth at the individual, species and genus level.
We also experiment with different degrees of variation of parameters between species
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and within species.

6.2.2

Ordinary Differential Equation Model

Virus concentration(log10 (PFU/mL))
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Figure 6.1: A sample ODE prediction for virus concentration (in log10 PFU/mL) over
time post infection (line) and simulated ground truth virus concentration (points).

We use a very simple model that simulates only viremia in serum, given by the
following differential equation:

dV
=a·V
dt

(6.2)

where V is the viral titer in serum in PFU/mL for a particular avian species. The
rate of increase in viral titer is given by a. The initial viral titer is denoted V0 .
The mass of the avian species is given by M . Assuming that an initial mosquito
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inoculated dose (Vdose , in PFU) is diluted in the whole body, gives the relationship
V0 = Vdose /M . The Bayesian model infers (Vdose ,a,M ) from the viral titer data.
The ordinary differential equations describing our viral kinetic models were solved
numerically in Matlab [31]. The Runge-Kutta 4 method of integration was employed
with a step size of 0.0004. Fig. 6.1 shows a sample plot of the ODE prediction of virus
concentration over time compared to simulated viral concentration reported every
day for four days. All model parameters and virus concentration are logged (base
10) in order to stabilize variance and ensure positive estimates from the Bayesian
inference.

6.2.3

Simulated Data

Table 6.1: Different combinations of between and within species variance
Variance
High between species variance
Low between species variance

High within
variance
(2.5,2.5)
(0.5,2.5)

species

Low within species variance
(2.5,0.5)
(0.5,0.5)

Number denotes variance on log10 scale

We generated simulated data in which viral titer increases with time as the infection progresses. We simulate data for 10 distinct groups (species) each having 3
individuals (for a total of 30 individuals). The initial mosquito inoculated dose, Vdose ,
is generated for the individuals by 30 independent draws from a normal distribution
N ormal(3.6, 1) (where p is the mean and q the variance in a normal distribution
N ormal(p, q)). We combined two levels of between-species variance with two levels of within-species variance to generate 4 sets of simulated viral titer data (Table
6.1). Each simulated dataset was generated in the following manner: we drew 10
species-level values from a distribution based on a particular value of between-species
variance; centered around each of these 10 values, we drew 3 more individual-level
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values based on the chosen value of within-species variance. This process yields 30
values (10 species each having 3 individuals) of ODE parameters, which are then
given to an ODE solver. The ODE solver generates a virus concentration that varies
over time (post infection) from which we take four samples to generate our ground
truth data.
All draws of (Vdose ,a,M ) are independent of each other in the data generation
process. Each individual has its own set of parameters (Vdose ,a,M ), which are then
given to the ODE solver that generates sampled data points from a simulated virus
curve. The data generation process produces a different virus titer curve for each
individual.

η, Λ

Ω, ν

µ

Σ−1
a, b

σ −2

θi

yi
n

Figure 6.2: Left Panel: Aggregated model with two groups combined. Each group
has three individuals. Also shown are the genus, species and individual levels. Right
Panel: Plate diagram for the aggregated model. The plate denotes iteration of
parameters and the number in the plate shows the number of iterations.
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6.2.4

Constraints on Model Parameters

The initial viral titer, Vdose , is constrained to be within 3 and 3 × 104 PFU/mL. The
rate of increase in viral titer, a, is constrained to lie within 0.01 and 100 /day, and
the mass, M , is constrained to be between 10−20 and 1020 kg.

6.2.5

Hierarchical Bayesian Model

Aggregated model
Given a population of individuals that belong to the same group, the hierarchical
Bayesian model assumes that the dynamics of infection of each individual is characterized by parameters (θi to θn for n individuals) that are drawn from a common
species-level distribution (µ).
The aggregated model has 10 species of 3 individuals each. The species are aggregated to form a tree of height 2. The model is shown graphically in Fig. 6.2
(Left panel). There are two levels in the hierarchical tree representation: individual
and all species combined into a single genus. Each level of the tree has an equation
describing the distribution of ODE model parameters (Eq. 6.2). The ith individual
has a parameter θi that represents the mean of (Vdose ,a,M ) for a particular individual. This parameter θi is then drawn from the genus level distribution (all species
aggregated) with mean µ. The mathematical details of the aggregated model are
given in Appendix A.

Multi-level hierarchical model
We also implemented a novel multi-level hierarchical model that has 3 taxonomic
levels and is a natural fit to the hierarchical structure of the data. This model has
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Figure 6.3: Left Panel: Multi-level hierarchical model with two groups. Each group
has three individuals. Also shown are the genus, species and individual levels. Right
Panel: Plate diagram for the multi-level hierarchical model. The plate denotes iteration of parameters and the number enclosed in the plate shows the number of
iterations.

10 groups (species) of 3 individuals each. The groups are arranged hierarchically to
form a tree of height 3. The model is shown graphically in Fig. 6.3 (Left panel) with
three levels in the hierarchical tree representation: individual, species and genus (Fig.
6.3, Right panel). Each level of the tree has an equation describing the distribution
of ODE model parameters (Eq. 6.2). The ith individual has a parameter θi that
represents the mean of (Vdose ,a,M ) for a particular individual. This parameter θi
is then drawn from a species-level distribution with mean µ. Finally, the specieslevel estimate is itself drawn from a genus-level distribution centered around η. The
mathematical details of the multi-level model are given in Appendix B.
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MCMC implementation

We are interested in inferring the posterior distribution of ODE parameters given
data (P (Θ|D), Eq. 6.1). However the distribution does not have an analytic form.
MCMC techniques enable us to sample from a target distribution; the approximation
gets better as more samples are drawn. We combine the Metropolis-Hastings algorithm and the Gibbs sampler. The Gibbs sampler is a type of MCMC algorithm that
divides the parameters into a number of components and at each iteration sequentially updates each of them by conditioning on the others. The Metropolis-Hastings
(M-H) algorithm updates Θ, and the Gibbs sampler updates all the remaining variables. We use a blockwise update scheme where proposed new values of parameters
(from the M-H algorithm) are either all updated simultaneously or all reverted to
their previous values. The M-H algorithm draws a subsequent sample from the target distribution centered around a proposal distribution. Our proposal distribution
is a multi-variate normal distribution centered around the current value of θi .
The choice of dispersion of the proposal distribution is important. If the dispersion is high, many MCMC moves will be rejected and the procedure will take longer
to converge. If the dispersion is low, the chain may not explore the parameter space
thoroughly [106, 107]. The standard deviation of the proposal distribution is chosen
to be 0.01 on the log scale (base 10) for all the parameters. If a value returned
by the proposal distribution is outside of the imposed bounds for ODE parameters,
we reflect the value back into range. Convergence is checked informally based on
graphical techniques [108].
All models were run for 3,000 iterations. This constitutes a single “run” of the
Bayesian model. One run of the Bayesian model may be more efficient when a number
of initial samples are discarded (burn-in) and when some number of consecutive
samples are not considered (thinning) [106]. The initial 300 iterations were discarded
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(burn-in phase). Of the remaining 2,700 samples we retained every fifth sample. The
same random number seed was used for both the models.

Individual level SSR Species level SSR

Genus level SSR

6.3

Results
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Figure 6.4: Performance on predicting genus, species and individual mean for ODE
parameter M : Multi-level model (blue) vs. aggregated model (red). Y-axis - sum of
squared residuals between predicted mean and actual mean (ground truth), X-axis variance between and within species (log scale) as described in Table 6.1.
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Figure 6.5: Performance on predicting species and genus level means for ODE parameters Vdose and a when there is high between-group and low within-group variance
in M : Multi-level model (blue) vs. aggregated model (red). Y-axis - sum of squared
residuals between predicted mean and actual mean (ground truth).

6.3.1

Estimates for ODE parameter M

The data generation phase produces ODE parameters by drawing from normal distributions with known mean and variance (ground truth). The exact values of ODE
parameters generated from the probabilistic draw constitute the sample truth.
Fig. 6.4 demonstrates the performance (defined as the sum of squared residuals
between predicted mean and actual mean) of the multi-level and aggregated models
at predicting genus, species and individual level means for the parameter M . All
analysis presented in the tables is from the same run.

106

Chapter 6. A Proof of Concept for Multi-Level Hierarchical Bayesian Models

We look at 4 different datasets that have varying amounts of between and within
species variation (shown in Table 6.1). The species-level performance is measured
by summing the sum of squared residuals between actual and predicted means over
all species. Similarly, the individual-level performance is measured by summing the
sum of squared residuals between actual and predicted means over all individual.
The multi-level model consistently makes better predictions of the genus level
mean value of M than its counterpart, regardless of the amount of variation between
and within species, as evidenced by lower sum of squared residuals for blue bars (Fig.
6.4).
We observe that if there is high between-group and low within-group variance
in M (Fig. 6.4), the multi-level model makes better predictions of ground truth at
the genus, species and individual levels than the aggregated model. In fact, given
large variation between species, the multi-level model appears to make more accurate
predictions at all levels. However, the aggregated model makes better predictions at
the species and individual level when there is less variation between species.

6.3.2

Estimates for ODE parameter Vdose

Fig. 6.5 shows the sum of squared residuals between predicted and actual mean at
the species and genus level for Vdose . The results shown here are for the case where
there is high between-group variance and low within-group variance in M . We focus
on this case because we expect our actual experimental data (Chapter 7) to have
high between-group and low within-group variance. The multi-level model performs
better at predicting species level means but is outperformed by the aggregated model
at the genus level. The results for Vdose were similar given other variations in M .
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Figure 6.6: Top panel - A plot of the ODE model prediction for all species combined.
Top Left panel - multi-level model, Top Right panel - aggregated model. X-axis days post infection, Y-axis - ODE predicted virus concentration (line) and simulated
data (points) in log10 PFU/mL. The multi-level model makes better predictions for
virus concentration time course with respect to the simulated data. Bottom panel Performance at predicting virus concentration in simulated data: Multi-level model
(blue) vs. aggregated model (red). Shown are SSR (sum of squared residuals) for
multi-level model predictions (species level SSR) and aggregated model predictions
(individual level SSR) for different between and within-species variances (Table 6.1).

6.3.3

Estimates for ODE parameter a

The sum of squared residuals between predicted and actual mean at the species
and genus level for a are shown in Fig. 6.5 (results shown for the case where there
is high between-group and low within-group variance in M ). Here the aggregated
model is able to better predict the means at both the species and genus level than
the multi-level model. The results shown here are for the case where there is high
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between-group variance and low within-group variance in M . The results for a were
similar given other variations in M .

6.3.4

Predictions of time course of virus concentration

The multi-level model is able to make better predictions of virus concentration over
time with respect to the simulated data. We generated a new set of simulated data
in the following manner. The data generation phase (see Simulated Data) generates
10 different distributions (Vdose ,a,M ) at the species level. We take the means of
each of these 10 distributions (separately) and create 10 different tuples (Vdose ,a,M ).
These species level ODE parameters are given to the solver to generate simulated
data sampled daily up to 4 days post infection.
We compare the multi-level and aggregated models to this simulated data using
3 methods:
1. Individual level SSR (multi-level): the multi-level model produces estimates
(distributions) of (Vdose ,a,M ) for each of the 30 individuals. For each species,
we take the average of the distributions of (Vdose ,a,M ) for the 3 individuals
that belong to that species. These ODE parameters are then given as input to
the solver that generates a virus concentration over time.
2. Species level SSR (multi-level): for each of the 10 species, the multi-level model
produces estimates (distributions) of (Vdose ,a,M ). We take the average of each
of these 10 distributions (separately) and obtain 10 different tuples (Vdose ,a,M ).
These ODE parameters are then given as input to the solver that generates
a virus concentration over time. We note that only the multi-level model
produces a prediction at the species level.
3. Individual level SSR (aggregated): similar to the first method, the aggregated
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model produces estimates (distributions) of (Vdose ,a,M ) for each of the 30 individuals. For each species, we take the average of the distributions of (Vdose ,a,M )
for the 3 individuals that belong to that species. These ODE parameters are
then given as input to the solver that generates a virus concentration over time.
The comparisons between the multi-level and aggregated models are shown in Fig.
6.6. The multi-level model produces better predictions of the time course of virus
concentration than the aggregated model (Fig. 6.6, Panel B), where the comparison
is done using any of the three methods described above. Ultimately this leads to
better predictions of time course of virus concentration after infection (Fig. 6.6,
Panel A).

6.3.5

ODE parameter correlations

We have observed that parameter correlations help constrain the parameter space
and produce narrower bounds on estimates [28]. Both the multiple level hierarchical
and the aggregated model showed correlations between parameters at the individual
level, e.g. log10 Vdose and log10 a had a statistically significant correlation (r2 = 0.44,
p-value = 0, OLS slope = -0.85) in the multi-level model for the case where there
is less within-species and more between-species difference. These correlations were
absent at the species and genus level in both the models.

6.4
6.4.1

Discussion
Summary of Results

Our analysis shows that the multi-level model makes more accurate predictions at
the species and genus levels if there is large variation in ODE parameters at the

110

Chapter 6. A Proof of Concept for Multi-Level Hierarchical Bayesian Models

species level. We are interested in the species level parameter estimates since the
hierarchical Bayesian model pools together information from diverse individuals at
that level. The species level gives a more nuanced estimate of how an entire group
of individuals behaves in response to infection.

6.4.2

Caveats and Limitations

We have larger variation (both on absolute and relative scales) in species mass (M )
than exists in the experimental infection data. The larger variation is chosen in
order to demonstrate the conditions under which the multi-level outperforms the
aggregated model.
The results presented here change if the between group variation in a is increased.
We believe that the dynamical system represented by the ODEs is especially sensitive
to a. Such behavior, where some parameters may be more susceptible to perturbations in parameter space than others, is typical of biological systems where one or
more parameters are stiff and account for a lot of variation in data [109, 110].
Finally, the analysis presented here is from one run of the hierarchical Bayesian
models. Although one run generates large amounts of data, since the Bayesian
models are stochastic, multiple independent runs would give more confidence in the
generality of the results.

6.4.3

Discussion

The multi-level model makes more accurate estimates of ODE parameters at the
species level and genus level when there is more between-species difference than
within-species difference in those parameters. For example, consider the case where
the ODE parameter M has more variation between species (2.5) than within (0.5).
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The multi-level model makes more accurate estimates of M at the species and the
genus level (Fig. 6.4).
The multi-level model also more accurately predicts time course of virus concentration with respect to simulated data (Fig. 6.6). The simulated data is generated
by taking species level estimates of ODE parameters from the data generation phase
and giving them as input to the ODE solvers.
We also observed that if an inferred parameter does not have phylogenetic dependence (say Vdose ) and is not hierarchically distributed then the aggregated model
outperforms the multi-level model in inferring estimates of that parameter (results
not shown).
Both the multi-level and aggregated models preserved ODE parameter correlations at the individual level. However these correlations were absent at the population
level in the multi-level model. This is of interest since we have observed that parameter correlations help constrain the parameter space and produce narrower bounds
on estimates [28]. In the absence of parameter correlations at the species and genus
levels, meaningful priors at these levels (such as we have in the multi-level model)
may help constrain parameter estimates to narrower and more biologically realistic
regimes.
Generally, a multi-level model applied to data with large between species variation
makes more accurate predictions than an aggregated model. This appears to be due
to the ability of the multi-level model to incorporate realistic priors at the species
level and more accurately simulate the hierarchical nature of a multi-species dataset.
Accurate predictions about time course of virus concentration (with respect to
simulated data, Fig. 6.6) enables the multi-level model to make better predictions of
parameters (Figures 6.4 and 6.5). The ability to make accurate predictions of ODE
parameters from data is important. Our analysis suggests that the multi-level model

112

Chapter 6. A Proof of Concept for Multi-Level Hierarchical Bayesian Models

will outperform an aggregated model on experimental data in which the true values
of ODE parameters are unknown.
The next chapter will examine the performance of the multi-level model in the
following realistic scenarios: we will have a more complex and biologically realistic
ODE model and the model will be trained on actual experimental data. We will
focus on a case where ODE parameters have more between-species variation than
within-species for all parameters (except Vdose ). Our objective will be to test model
parameters characterizing WNV infection and host immune response for dependence
on host (species) body mass.
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Chapter 7
A Hierarchical Bayesian Model of
Body Size Effects on Pathogen
Replication and Immune System
Response

7.1

Introduction

Many emerging pathogens infect multiple host species [8], and multi-host pathogens
may have very different dynamics in different host species [9]. Diseases that jump the
species barrier from animals to humans (zoonotic diseases) cause 2.5 billion cases of
human illness and 2.7 million human deaths per year [10]. Many emerging diseases
are zoonotic in origin.
Understanding how quickly pathogens replicate and how quickly the immune system responds is important for predicting the epidemic spread of emerging pathogens.
Host body size, through its correlation with metabolic rates, is theoretically predicted
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to impact pathogen replication rates and immune system response rates [6]. Prior
work suggests that body mass affects pathogen replication rates [9, 38, 26], but immune response times are either independent of mass or increase only very slowly
as mass increases [26, 57]. Here, I use mathematical models of viral time courses
from multiple species of birds infected by WNV to test more thoroughly how disease
progression and immune response depend on mass and phylogeny.
Phylogeny is an important determinant of the pathogenesis of WNV. Passerine species sustain more viremia than non-Passerine species [5]. Corvid species are
particularly susceptible to WNV infection [5]. Therefore, any analysis of disease dynamics in multi-host pathogens like WNV should take phylogeny into account. We
accomplish this using hierarchical Bayesian models that incorporate the hierarchical
nature of phylogeny.
The role of phylogeny in determining WNV infection outcome is known qualitatively [5]. We aim to provide a quantitative prediction for viral competency for
Passerines and corvids in particular. Further, the fits to experimental data using
our mathematical models enable us to form hypotheses as to why WNV viremia is
higher in these groups.
Hierarchical Bayesian models enable modelers to encapsulate knowledge about
the underlying biology as priors. Suitable priors in a hierarchical Bayesian framework can help reduce variance of parameter estimates [13] and possibly produce
more accurate parameter estimates. The previous chapter validated the hierarchical
Bayesian models and showed that a model that incorporates the hierarchal nature of
phylogeny and encodes this information as priors in a hierarchical Bayesian model,
may enable more accurate estimates of parameters characterizing WNV infection.
The present chapter extends the models in the previous chapter by applying them
to actual experimental data.
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We also calculate a reservoir competence index that indicates the relative number
of infectious mosquitoes that would be derived from feeding on these hosts.
This chapter extends the work in the previous chapter by applying hierarchical
Bayesian models to actual experimental data while using a more biologically realistic
ODE model of WNV replication and immune response. The goals of this chapter
are:

1. To test if a multi-level model produces more accurate estimates of virus concentration over time (with respect to experimental infection data) than an
aggregated model.
2. To test model parameters characterizing WNV infection and host immune response for dependence on host (species) body mass and phylogeny.

7.2
7.2.1

Materials and Methods
Overview of Methods

The multi-level hierarchical Bayesian model mimics the hierarchical nature of phylogeny. There are three levels in the hierarchical tree representation: individual,
species and order (Fig. 6.3). Each level of the tree has an equation describing the
distribution of differential equation model parameters. The differential equations
and hierarchical Bayesian models are explained in greater detail in the next section.
Our goal is to compare two different hierarchical Bayesian models: a multi-level
model that has three levels of hierarchy (for individual, species and order) and an
aggregated model with two levels of hierarchy (all individuals of all species pooled
together under a single top level entity) (Fig. 6.2). Each of these Bayesian models
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is run on 3 different kinds of experimental data: all Passerine and non-Passerine
species combined, Passerine and non-Passerine species separately and finally only
corvid species (a subset of Passerines).

Virus concentration in blood (log10 PFU/mL)

7.2.2

Ordinary Differential Equation Model

8

simulated
actual data

7

6

5

4

3

2
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1

2

3

4

5

6

Time post infection (days)

Figure 7.1: A sample ODE prediction for virus concentration (in log10 PFU/mL)
over time post infection (blue) and experimental data on virus concentration (red).
Data show viremia of great-horned owls from [5].

We use two models that simulate viremia in serum. The first model assumes that
the infection is target-cell limited in birds, i.e. the concentration of virus reaches
a peak and then declines when few susceptible target cells remain. The model is
the same as the target-cell limited model for mice (Chapter 5, Eqs. 5.1-5.4). The
Bayesian model infers (V0 ,β,p,δ) from the viral titer data. The ordinary differential
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equations describing our viral kinetic models were solved numerically in Matlab [31].
The Runge-Kutta 4 method of integration was employed. All model parameters and
virus concentration are logged (base 10) in order to stabilize variance and ensure positive estimates from the Bayesian inference. A sample plot of the ODE prediction of
virus concentration over time (compared to observed data about virus concentration)
is shown in Fig. 7.1.
We also use a more sophisticated model that assumes viral decline is due to an
adaptive antibody (induced IgM) response (same as the adaptive immune response
model in mice, Chapter 5, Eqs. 5.7-5.11). The Bayesian model infers (V0 ,β,p,δ,ρ,ti )
from the viral titer data.

7.2.3

Constraints on Model Parameters

The model constraints are summarized in Table 7.2. The initial density of uninfected
target cells, T (0), is fixed to 2.3 × 105 /mL (mean of the estimated range in mice,
Chapter 5, [28]). The rate of clearance of free infectious virus,γ, is set to 44.4 /day
(upper bound of estimate in mice, [28]) for all species except three corvids (Fish
crows, Blue jays and American crows) for which we could get good fits with only a
lower value (1 /day).
The eclipse phase of virus, 1/k, is fixed to the lower bound of a range from wildtype mice (6 hours, see Chapter 5, [28]). Similarly, based on calculations in wildtype
mice (Chapter 5), the lifetime of productively infected cells, 1/δ, is constrained to be
greater than 1 hour while obeying the relationship 1/δ + 1/k = 24 hours. Finally, the
rate of antibody production (η) is fixed at 54.7 /day [28] and the time of initiation
of antibody, ti , is bounded between 2 and 4 days [28] based on experimental data or
model fits to experimental data in wildtype mice.
The infectious virion burst size, p/δ, is constrained to not exceed 1012 PFU based
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on fits of the target cell limited model to birds. Similarly, the efficacy of antibody
−1
neutralization, ρ, is bounded between 0.05 and 1000 PRNT−1
50 day based on model
fits to experimental infection data on birds. The initial viral titer, V0 , is constrained

to be within 0.1 and 1012 PFU/mL and the rate of production of virus, p, is constrained to lie within 0.5 and 1012 /day based on fits in birds.

7.2.4

Experimental data

WNV infects bird species ranging from 3 gm sparrows to a 3 kg geese. This wide
range of species mass allows us to test the effects of animal body size on pathogen
replication and immune response. We focus on data from a study which experimentally infected animals with the same strain of WNV (WNV NY99-6480). Komar et
al [5] experimentally infected 25 species of birds with WNV NY99-6480 and took
daily measurements of the concentration of infective virions in blood (viremia) over
the course of infection (sample plot shown in Fig. 1, data points in red). Viremia
was reported in Plaque Forming Units (PFU).
From this experimental dataset we excluded data on 2 species (Japanese quail
and ring-necked pheasant). The virus kinetics in Japanese quail were erratic and
viremia levels in the ring-necked pheasant were approximately constant over time;
as such these species could not be simulated by our model.
The Passerine species are the common grackle, American robin, red-winged blackbird, house finch house sparrow and corvids. The corvid species are fish crows, blue
jays, American crows and black-billed magpies.
The experimentalists also reported the Level of Detection (LOD) of their viral
assay as 101.7 PFU. The raw experimental data had reports of consecutive viral
measurements at LOD in the declining phase of viremia for some species. In these
cases we only considered the first occurrence of LOD in the time series and discarded
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the remaining. Considering all LOD data points would have led our models to an
underestimate of the slope of the declining phase due to the flat trajectory induced
by multiple consecutive viremia measurements at the same level.

7.2.5

Hierarchical Bayesian Model

Aggregated model
Given a population of individuals that belong to the same group, the hierarchical
Bayesian model assumes that the dynamics of infection of each individual is characterized by parameters (θi to θn for n individuals) that are drawn from a common
species-level distribution (µ).
The aggregated model has 23 species. The species are aggregated to form a tree
of height 2. The model is shown graphically in Fig. 6.2 (Left panel). There are two
levels in the hierarchical tree representation: individual and all individuals (of all
species) combined. Each level of the tree has an equation describing the distribution
of ODE model parameters (Eq. 5.1-5.4 and Eq. 5.7-5.11). The ith individual has
a parameter θi that represents the mean of (Vdose ,a,M ) for a particular individual.
This parameter θi is then drawn from a higher distribution (all species aggregated)
with mean µ. The details of the model are given in the Appendix A.

Multi-level hierarchical model
We also devised a multi-level hierarchical model that has 23 groups (species). The
groups are arranged hierarchically to form a tree of height 3. The model is shown
graphically in Fig. 6.3 (Left panel). There are three levels in the hierarchical tree
representation: individual, species and order (Fig. 6.3). Each level of the tree has
an equation describing the distribution of ODE model parameters (Eq. 5.1-5.4 and
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Eq. 5.7-5.11). The ith individual has a parameter θi that represents the mean of
(Vdose ,a,M ) for a particular individual. This parameter θi is then drawn from a
species-level distribution with mean µ. Finally, the species-level estimate is itself
drawn from a order-level distribution centered around η. The details of the model
are given in the Appendix B.

MCMC implementation
The details of the MCMC implementation are described in Chapter 6. All models
were run for 10,000 iterations. This constitutes a single “run” of the Bayesian model.
The initial 1000 iterations were discarded (burn-in phase). Of the remaining 9,000
samples we retained every fifth sample.

Calculation of averages for ODE parameters at different levels of hierarchy
We use the posterior samples of ODE parameters to generate the averages in the
following way: for each individual, species or order we have 10,000 samples originally
(as described in the previous section) at that level of the hierarchy. After burn-in
this is reduced to 9000 samples and thinning of the samples leads to a total of 1800
samples. The average of these samples (henceforth referred to as individual-level,
species-level or genus-level averages) for each ODE parameter (V0 , β, p, δ) is used in
the Results section.

Calculation of reservoir competencies
We calculate a reservoir competence index that indicates the relative number of infectious mosquitoes that would be derived from feeding on each host species and
is calculated from the viremia that develops in the hosts after infection. We ex-
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tend a competence index developed by Komar et al [5] to account for time-varying
viremia. Species that sustain WNV viremia above 105 PFU/mL are considered infectious for mosquito vectors [5]. The reservoir competence index (Ci ) is a function
of susceptibility (s), the proportion of birds that become infected as a result of daily
exposure; mean daily infectiousness (i), the proportion of exposed mosquito vectors that become infected per day; and the duration of infectious viremia above a
threshold (d) [5]. Komar et al [5] calculate the competence as Ci = s × i × d where
i=

log10 (Vp )−5
10

+ 0.02 and Vp is the peak viremia attained by a host; this assumes that

hosts sustain a fixed viremia (at the level of peak viremia) throughout the duration
of infectivity.
Our competency index for each species is calculated as follows:
Z td
Ci = s ×
i(t)dt

(7.1)

0

i(t) =




log10 V (t)−5
10



+ 0.02 , log10 V (t) ≥ 5

(7.2)

0 , log10 V (t) < 5

where td is the time until viremia is measured experimentally, i(t) is the infectivity
at time t and V (t) is the ODE model predicted viremia at time t. Following bird
mortality calculations made in Komar et al [5], we set the susceptibility (s) to be 0.7
for Budgerigars and 1 for all other species.

7.3
7.3.1

Results
Accuracy in viremia prediction

We estimated accuracy of viremia prediction by calculating three different estimates
of a sum of squared residuals (SSR) between data and ODE prediction (for both the
multi-level and aggregated Bayesian models):
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Figure 7.2: Top panel: Accuracy in viremia prediction between multi-level model
(blue) and aggregated model (red) for three different levels - individual, species
and order. SSR - sum of squared residuals between model predicted viremia and
data. Bottom panel: A sample viremia prediction from the multi-level (blue) and
aggregated model (red).

1. Individual-level SSR. We calculated individual-level averages of ODE parameters for each species as described in Section 7.2.5. For each individual, we
used these individual-level ODE estimates to generate a SSR between data
and model prediction in the following way: for each individual in a species,
we gave the ODE solver the individual-level parameter estimates and calculated the SSR between model prediction and individual-level data. The SSR
was then summed up for all individuals of all species and then divided by the
number of individuals. We call this the individual-level SSR.
2. Species-level SSR. We calculated species-level averages of ODE parameters for
each species as described in Section 7.2.5. For each species, we used these
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Figure 7.3: Scaling of biologically relevant quantities with host mass for the multilevel model: Passerines (black square and black regression line, non-Passerines (red
circle and red regression line) and all combined (blue regression line). Top left: Peak
viremia (Vp ), slope = -0.82, p-value = 0.06, r2 = 0.04. Top right: WNV production
rate (p), slope = -1.1, p-value = 0.002, r2 = 0.11. Bottom left: Inoculated density
of virions (V0 ), p-value = 0.35. Bottom right: R0 , slope = -1.3, p-value = 0.006, r2
= 0.09.

species-level ODE estimates to generate a SSR between data and model prediction in the following way: for each individual in a species, we gave the ODE
solver the species-level parameter estimates and calculated the SSR between
model prediction and individual-level data. The SSR was then summed up for
all individuals within a species and then for all species and then divided by the
number of individuals. We call this the species-level SSR.
3. Order-level SSR. We calculated order-level averages of ODE parameters for
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Table 7.1: Statistics of scaling relationships with species mass (all species combined)
from multi-level model with target cell limitation (TCL) or adaptive immune response (AIR)
Parameters

Combined
slope

p-value

r2

p (TCL): WNV production rate

-1.1

0.002

0.11

p (AIR): WNV production rate

-0.84

0.04

0.05

R0 (TCL): Basic reproductive number

-1.3

0.006

0.09

R0 (AIR): Basic reproductive number

-0.57

0.08

0.04

p/δ (TCL): Burst size

-1.1

0.001

0.12

p/δ (AIR): Burst size

-0.86

0.03

0.06

Vp (TCL): Peak viremia

-0.82

0.06

0.04

Vp (AIR): Peak viremia

-

0.54

0.005

V0 (TCL): Inoculated WNV density

-

0.35

0.1

V0 (AIR): Inoculated WNV density

-

0.1

0.03

β (TCL): WNV infectivity

-

0.64

0.003

β (AIR): WNV infectivity

-

0.39

0.009

δ (TCL): Death rate of productively in- fected cells

0.6

0.003

δ (AIR): Death rate of productively in- fected cells

0.51

0.005

ρ (AIR): Rate of adaptive immune sys- tem mediated virus neutralization

0.11

0.03

ti (AIR): Time of initiation of IgM re- sponse

0.56

0.004
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Figure 7.4: Posterior distribution of log10 R0 and burst size (log10 p/δ) for the multilevel model (target cell limited model). Top panel: Multi-level model with all Passerines (red), corvids (green) and non-Passerines (blue). Middle panel: Multi-level
model with only Passerines (red) and corvids (green). Bottom panel: Multi-level
model with only corvids (green).

each species as described in Section 7.2.5. For each individual, we used these
order-level ODE estimates to generate a SSR between data and model prediction in the following way: for each individual in a species, we gave the ODE
solver the genus-level parameter estimates and calculated the SSR between
model prediction and individual-level data. The SSR was then summed up for
all individuals of all species and then divided by the number of individuals. We
call this the genus-level SSR.
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We observed that the multi-level model produced more accurate estimates at the
individual-level and species-level (Fig. 7.2, top panel). A representative viremia
prediction for both the multi-level and aggregated model is also shown (Fig. 7.2,
bottom panel). The performance of both the models at the order-level were similar.

7.3.2

Scaling of biologically relevant quantities

We looked at the correlation between individual-level averages of ODE parameters
and species mass (Fig. 7.3) for the multi-level model. The scaling relationships and
statistics are summarized in Table 7.1. We observed that the production rate of
infective virions (p, PFU /day) is correlated with species mass (all species combined:
p-value = 0.002, r2 = 0.11, slope = -1.1; only Passerines: p-value = 0.04, r2 = 0.1,
slope = -1).
The basic reproductive number, R0 , had a significant overall correlation with mass
(all species combined: p-value = 0.006, r2 = 0.09, slope = -1.3; only Passerines:
p-value = 7 × 10−5 , r2 = 0.33, slope = -3.7). Peak viremia (Pv , the maximum
viremia attained by an individual over the time course of infection) had a marginally
significant correlation with species mass (all species combined: p-value = 0.06, r2 =
0.04, slope = -0.82).
The burst size (p/δ, PFU) had a significant relationship with species body mass
(all species combined: p-value = 0.001, r2 = 0.12, slope = -1.1; only Passerines:
p-value = 0.03, r2 = 0.12, slope = -1.1). Also the viremia at day 1 (V (1)) was
correlated with mass (all species combined, p-value = 0.003, r2 = 0.1, slope = -1.1).
The density of inoculated virions (V0 ) and the infectivity of WNV (β) had no
significant relationship with species mass (all species combined: p-value = 0.35,
r2 = 0.1 and p-value = 0.64, r2 = 0.003, respectively). Finally, the death rate
of productively infected cells (δ, /day) had no relationship with mass (all species
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combined, p-value = 0.6).
We also used the adaptive immune response model (Eqs. 6.5-6.9) to investigate
how parameters related to the immune response scale with host body mass (multilevel model, Fig. 7.6 and Table 7.1). The rate of adaptive immune system mediated
−1
neutralization of virus (ρ, PRNT−1
50 day ) did not have a significant relationship
with body mass (all species combined: p-value = 0.11, r2 = 0.03, slope = -0.19),

although we observed that in Passerines it declined significantly with mass (p-value
= 0.04, r2 = 0.1, slope = -0.51). The time of initiation of IgM response (ti ) also did
not have a significant relationship with species mass (all species combined: slope =
0.002, p-value = 0.56, r2 = 0.004; only Passerines: slope = 0.01, p-value = 0.07, r2
= 0.08).

7.3.3

Effect of phylogeny on parameter estimates

We investigated the effect of phylogeny on two biologically relevant quantities - the
basic reproductive number (R0 ) and the burst size. The basic reproductive number
represents the average number of second generation infections produced by a single
infected cell placed in a population of susceptible cells. If R0 is greater than 1, then
an infection can be established, whereas an infection rapidly dies out if R0 is less
than 1. For the target cell limited model (Eqs. 5.1-5.4), R0 is given by [99]:

R0 =

pβT0
δ(γ + β · T0 )

(7.3)

The burst size, p/δ, represents the number of infectious virions released by an
infected cell over its productively infected lifespan. Estimates of the mean values of
R0 from the multi-level model are higher for Passerine species (23.8) compared to
non-Passerines (4.7) (Fig. 7.4, top panel). Within Passerines, corvid species (fish
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Figure 7.5: Posterior distribution of log10 R0 and burst size (log10 p/δ) for the aggregated model (target cell limited model). Top panel: Aggregated model with all
Passerines (red), corvids (green) and non-Passerines (blue). Middle panel: Aggregated model with only Passerines (red) and corvids (green). Bottom panel: Aggregated model with only corvids (green).

crows, blue jays, American crows and black-billed magpies) have the highest value
of R0 (93.2) (Fig. 7.4, top panel). Finally, estimates of R0 in the aggregated model
(Fig. 7.5) are orders of magnitude higher than in the multi-level model (Fig. 7.4).

7.3.4

Estimates of reservoir competence

We calculated a reservoir competence index that indicates the relative number of
infectious mosquitoes that would be derived from feeding on these hosts (Section
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Figure 7.6: Scaling of immune response parameters with host mass for the multilevel model with immune response: Passerines (black square) and non-Passerines (red
circle). Left panel: Rate of adaptive immune system mediated virus neutralization
−1
(ρ, PRNT−1
50 day ). Right panel: Time of initiation of IgM response (ti , days)
(combined and each group separately are non-significant).

7.2.5). The reservoir competency indices we calculate are correlated with and approximately half of the estimates in Komar et al [5] (Fig. 7.7, r2 = 0.94, slope =
0.54, p-value = 0).

7.4
7.4.1

Discussion
Summary of Results

A multi-level hierarchical model informed by phylogeny more closely matches empirical viremia than an aggregated model (Fig. 7.2). The multi-level model also
produces more reasonable estimates of biologically relevant quantities like the basic
reproductive number and burst size (Fig. 7.4 and 7.5). The multi-level model pre-
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Figure 7.7: Correlation between multi-level model predicted competency and competency from Komar et al [5] assuming static viremia (r2 = 0.94, slope = 0.54, p-value
= 0)

dicted WNV production rate decreases with species mass, consistent with theoretical
predictions from metabolic scaling theory (Fig. 7.3).

7.4.2

Discussion

Hierarchical Bayesian models are a principled method to aggregate data from multiple related individuals while still doing fits to data at the individual level. Here
we use a multi-level hierarchical model to incorporate phylogeny and pool infection
data from related species. We observe that the multi-level model produces more
accurate predictions of viremia at the individual and species level when compared to
hierarchical models that have fewer levels of hierarchy (Fig. 7.2).
Additionally, multi-level models with Passerines and non-Passerines or just
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Passerines (Fig. 7.4, top and middle panels) produced more realistic and well peaked
distributions of R0 and burst size, than a multi-level model with only corvids (Fig.
7.4, bottom panel) and the aggregated model (Fig. 7.5). This appears to be due
to the ability of multi-level models to pool information at the species level from
disparate individuals both within and between different species.
The mean values of R0 from the multi-level model are higher for Passerine species
(23.8) compared to non-Passerines (4.7) (Fig. 7.4, top panel). Within Passerines,
corvid species have the highest value of R0 (mean 93.2). Burst sizes of Passerine
species (8690 PFU) are much higher than those in non-Passerines (340 PFU) (Fig.
7.4, top panel). This appears to be consistent with experimental studies that found
Passerines and corvids have higher reservoir competency (ability to transmit infection to mosquitoes) than non-Passerines [5]. Overall, phylogeny emerges as a key
determinant of biologically relevant quantities like the basic reproductive number
and burst size.
The mean values of R0 from the multi-level model for Passerine species (23.8) is
also higher than the corresponding model predicted value in mice (mean R0 = 2.5,
Chapter 5). The infectious virion burst size of Passerine species (8690 PFU) is also
significantly higher than model estimates from fitting data in mice (mean infectious
virion burst size = 3 PFU, Chapter 5).
Individual cellular metabolic rates and times, if constrained by host metabolism,
are expected to scale with host body mass as M −1/4 and M 1/4 , respectively. We
observe that the production rate of infectious virions (p, /day) declined significantly
with host body mass. There is large scatter but the 95% confidence interval (CI) for
the slope ([-1.5 0.03]) includes the theoretically predicted exponent of -0.25 (Fig. 7.3).
However, the death rate of productively infected cells (δ, /day), also theoretically
predicted to increases with mass, had no relationship with species mass. Lastly, the
basic reproductive number (R0 ), declined significantly with body mass (Fig. 7.3)
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and the relationship is even more significant within Passerine species. This is most
likely due to the fact that the production rate of virions (p), a component of the R0
(Eq. 7.3), declined with mass.
We found that the mean of peak viral concentration in serum (peak viremia)
declines with species body mass (Fig. 7.3) although the correlation was marginally
significant. Additionally, most Passerine species had higher peak viremia than nonPasserines. This is likely due to the fact that most of the Passerine species had a
higher value of production rate (p) than the non-Passerines. Overall, we observed
scaling of some biologically significant parameters with mass which were modified
from theoretical scaling predictions by the influence of phylogeny.
The density of inoculated virions (V0 ) has no significant relationship with species
mass (Fig. 7.3). This is surprising since if mosquitoes inoculated a fixed dose directly
into the host bloodstream, the density of virions (V0 ) would be expected to decline
with host mass since the dilution would be higher in the larger blood volume of
a larger species. Mosquito inoculated WNV, that is initially localized at the site
of infection [34], is taken up by immune cells to nearby lymph nodes and thereby
traffics to different organs via the bloodstream. Our results point to the importance
of accounting for spatial patterns of viral spread, especially in the initial stages of
an infection when virus is localized. However for computational efficiency we use
differential equation models that ignore space and assume that all components are
well mixed.
We calculated a reservoir competence index that indicates the relative number
of infectious mosquitoes that would be derived from feeding on these hosts (Section 7.2.5). Our reservoir competency index is a refinement on previously published
indices [5] since they take time-varying viremia and species relatedness (via the multilevel Bayesian model) into account. The reservoir competency indices we calculate
are correlated with and approximately half of the estimates in Komar et al [5] (Fig.
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7.7). The mean reservoir competence for Passerine species (0.8) is higher than that
of non-Passerines (0.2).
We used the adaptive immune response model (Eqs. 5.7-5.11) to investigate
how parameters related to the immune response scale with host body mass (multilevel model, Fig. 7.6). The rate at which the adaptive (antibody) immune response
neutralizes virus (ρ) did not have a significant relationship with body mass, although
we observed that in Passerine species it declined significantly with mass. The time
of initiation of the adaptive (antibody) immune response (ti ) also did not have a
significant relationship with species mass.
The target-cell limited and adaptive immune response models both produce similar scaling predictions (when coupled to the multi-level hierarchical model) (Table
7.1), e.g. both viral dynamics models predict that the production rate of WNV (p)
declines with species mass.
In summary, we investigated the effect of body size in the immune system which
is a complex, non-linear dynamical system. Previous scaling work has focussed on
easily observable attributes such as lifespan or fertility rate [11, 12]. In contrast,
in-vivo viral production rates and immune response rates must be inferred by fitting
mathematical models to empirical data such as the viremia curves we use here.
Here we use a multi-level model hierarchical Bayesian model to infer parameters
such as viral production rate for multiple species. This leads to new hypotheses
about the mechanisms that cause certain taxonomic groups to have higher viremia.
For example, our models suggest that higher burst sizes cause corvids to harbor
higher WNV viremia (Fig. 7.4).
Our modeling also suggests that rates of WNV production decline with species
mass whereas rates and times related to the adaptive immune response do not vary
systematically with mass. Taken together, these results provide an understanding of
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how epidemiological determinants like peak viremia vary with species body mass.
Peak viremia is an important epidemiological determinant for the spread of WNV
[5]. Above a threshold peak viremia of 105 PFU/mL of blood, a host is capable of
infecting an uninfected mosquito, and maintain WNV in an enzootic cycle [5]. Hence
hosts that can sustain peak viremia above this threshold and for a longer duration are
pathogen reservoirs. The dependence of peak viremia on host mass and phylogeny
may give important insights into the role of mass and phylogeny on the spread
of WNV. For example, larger non-Passerine species, predicted to have lower peak
viremia, may be less competent as pathogen reservoirs.
Our viral dynamics models take complex non-linear interactions at the level of the
immune system of individuals into account. The hierarchical Bayesian models then
aggregate these dynamics across multiple disparate individuals and make predictions
at different phylogenetic levels. The methods and approaches developed here are
likely to be applicable to modeling of other multi-host pathogens that have significant
differences in dynamics between species. These techniques may also be broadly
applicable to modeling of other complex systems with non-linear interactions at
different levels of organization.
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Table 7.2: Parameter constraints of target cell limited and adaptive immune response
model in birds
Parameters Description
Estimated Ranges
Source
γ

WNV clearance 44.4/day for non- Value for non-corvids estirate
corvids and 1/day for mated from fit to viral decorvids
cay study in wildtype mice
[4] (Chapter 5)

η

Rate of IgM pro- 54.7/day
duction

Fit to antibody titer study
in wildtype mice [73] (Chapter 5)

T0

Initial target cell 2.3 × 105 /mL
density

Average of estimated range
in mice from [89] (Chapter
5)

k

Rate of transi- 4/day
tion from I1 to I2

Upper bound of estimate in
mice from [90, 91] (Chapter
5)

1/δ

Lifetime
of ≤ 24 − 1/k days
productively
infected cells

Calculations in mice (Chapter 5)

ti

Time of initi- 2 - 4 days
ation of IgM
response (days
post infection)

Estimates in
(Chapter 5)

V0

Initial viral titer 0.1 - 1012 PFU/mL

Model constraint in birds

p

Rate of WNV 0.5 - 1012 /day
production

Model constraint in birds

p/δ

Infectious virion ≤ 1012 PFU
burst size

Model constraint in birds

ρ

Efficacy of anti- 0.05
−1
body neutraliza- PRNT50 day−1
tion
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Chapter 8
Conclusions

How different is the immune system of a mouse from that of a human? Do pathogens
replicate at the same rate in all species? Diseases that jump the species barrier from
animals to humans affect millions worldwide. An understanding of how disease progression and immune response vary from species to species could have important
public health consequences. This thesis attempts to understand how immune function scales with body size and is a foundation for future work to investigate scaling
of immune response to other pathogens or in other animals. A theory of scaling for
the immune system could also have implications for performance scaling in humanengineered systems that draw inspiration from the immune system.
This dissertation analyzed how species body mass and phylogeny affect the arms
race between pathogens and the host immune system in the specific case of WNV.
In Chapter 3, we showed immune response rates and times are nearly invariant
with body mass and how the physical architecture of the immune system facilitates
this. In Chapter 4, we showed how chemical signals in the immune system facilitate
efficient search for infected cells. Chapter 5 showed that we can predict biologically
relevant quantities characterizing WNV infection with precision despite uncertainty
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in individual model parameters. In Chapter 6, we showed that using a hierarchical
Bayesian model to reflect phylogenetic relationships can help make more accurate
estimates of model parameters.
Finally, in Chapter 7, we applied our hierarchical model to empirical data and
observed variation of biologically relevant quantities with species mass and phylogeny. The rate at which WNV is produced by infected cells declines with species
mass. Since times scale inversely as rates, this is consistent with findings in Cable
et al [9] who observed that time to death in WNV infections increased with species
mass. Overall, we observed scaling of some biological significant parameters with
mass which were modified from theoretical scaling predictions by the influence of
phylogeny. Taken together, species mass and phylogeny provide mechanistic insights
into why some species (for example, smaller Passerines) are pathogen reservoirs.

8.1

Implications for spread of zoonotic diseases

A critical level of viremia in blood is necessary for a host to infect to uninfected
mosquitoes which can then sustain WNV in an enzootic cycle by potentially infecting
other susceptible hosts. Some small Passerine species are presumed to be pathogen
reservoirs.
Our analysis suggests an important role for both species mass and phylogeny in
dictating epidemiological determinants like basic reproductive number, WNV production rate, peak viremia in blood and host competency to infect mosquitoes. Our
model is based on a principled analysis and gives a quantitative prediction for key
epidemiological determinants and how they vary with species mass and phylogeny.
The WNV production rate (p) and the basic reproductive number (R0 ) decline with
host body mass (Fig. 7.3). The relationship is even more significant within Passerine
species (Fig. 7.3).
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Our models lend mechanistic insight into why some species (smaller Passerine
species) are pathogen reservoirs and some (larger non-Passerine species) are potentially dead-end hosts for WNV. Our techniques give insights into the role of mass
and phylogeny in the spread of WNV and potentially other zoonotic diseases.

8.2

How the immune system achieves
scale-invariance

In sharp contrast to the vast majority of biological rates that slow systematically
as body size increases [11, 12], the rate at which the adaptive (antibody) immune
response clears WNV and the time at which it is initiated do not vary systematically
with mass (Fig. 7.6). We suggest two plausible mechanisms for this scale-invariant
search and response:1. The physical architecture of the immune system. In Chapter 3, we proposed
that a sub-modular architecture of lymph nodes, that balances local pathogen
detection and global antibody production, may lead to nearly scale-invariant
search and response times. Reducing time taken to traffic pathogens from tissue
to lymph nodes requires numerous small lymph nodes. However a larger lymph
node can recruit more immune system cells and speed up response against
the pathogen. The optimal architecture that balances the opposing demands
of local pathogen detection and global response is one in which lymph node
number and sizes both increase with animal size.
2. Signaling in the immune system. Chemical signals released from infected sites
help guide immune system cells towards infected regions. Chapter 4 showed
that these inflammatory signals lead to efficient search in the immune system
and the speedup in search due to these signals is higher in larger animals.
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Our model (Chapter 3) predicted time to initiate the adaptive antibody response
(ti ) is a combination of: the time to detect WNV by dendritic cells (tDC
detect ), the
time taken by antigen-loaded dendritic cells to migrate to the draining lymph node
(tDC
migrate ), the time taken by dendritic cells to present antigen to the antigen-specific
cell
cognate T-cells (tDC,cT
) and the time taken by the immune system to recruit a
detect

critical number of B-cells and then secrete a critical amount of antibody into blood
(trecruit ). We suggest that the architecture of the immune system has evolved to
minimize ti . Minimizing tDC
migrate requires having more lymph nodes of smaller sizes
since each lymph node would have a smaller draining region over which dendritic
cells migrate. Minimizing trecruit requires having fewer but larger lymph nodes since
a larger lymph node can recruit more immune system cells. The architecture that
balances the opposing demands of local trafficking and global recruitment of immune
system cells is one in which the number of lymph nodes and their sizes both increase
with animal body size. Our modelling suggests that this would lead to nearly scaleinvariant search and response: ti ∝ M 1/7 , where M is the mass of the animal.

8.3

Implications for human-engineered
distributed systems

The immune system can be viewed as a computational system that implements a
remarkably efficient distributed search for pathogens. Our work suggests that immune responses are nearly as fast in small and large systems. Understanding how
the immune system scales up efficiently is important in the design of human engineered systems that are inspired by the immune system. Many distributed systems
are engineered to solve analogous problems, and the immune system demonstrates
how such engineered systems can achieve desirable scalability. We propose that the
physical architecture of the immune system can be emulated to design more efficient
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human-engineered distributed systems [54, 26].
The immune system balances the opposing demands of local communication
(pathogen detection) and global communication (antibody production). We showed
that similar tradeoffs can exist in distributed systems like immune system inspired
multi-robot systems and peer-to-peer systems [54, 26]. Taking inspiration from the
architecture of the immune system, we proposed a modular RADAR (Robust Adaptive Decentralized search with Automated Response) strategy for distributed systems. We demonstrated how two existing distributed systems (a multi-robot control
application and a peer-to-peer system) can be improved by a modular RADAR strategy. Such a sub-modular architecture is shown to balance the tradeoffs between local
communication (within peer-to-peer clusters) and global communication (between
peer-to-peer clusters), leading to efficient search for rare amounts of information.
Finally, our immune-inspired modular RADAR strategies can be extended to
other distributed systems like intrusion detection systems and cellphone networks.
Testing the modular RADAR strategy on an implemented mobile multi-robot system
to verify our predictions could also be the subject of future investigations.

8.4

Modeling framework for studying multi-host
pathogens

This thesis introduced a technique to infer parameters characterizing viral production
and immune response across multiple species. The technique involves using hierarchical Bayesian models to encapsulate differences between species as priors. Suitable
priors in a hierarchical Bayesian framework can help reduce variance of parameter
estimates [13] and possibly produce more accurate parameter estimates, as shown in
Chapter 6. To the best of our knowledge, Bayesian non-linear mixed effects models
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with multiple levels of hierarchy have not been previously applied to within-host
modeling.
Mathematical models that combine within-host experimental data from multiple
species, such as the ones presented here, may be useful in studying other zoonotic
diseases and help increase our understanding of these diseases. Hierarchical Bayesian
models coupled to within-host viral dynamics models can be used to model other
zoonotic diseases and multi-host pathogens. Our analysis also suggests that this
approach will likely produce more accurate parameter estimates when there is more
variation between species than within.

8.5

Implications for translational research

Most immunological experiments are conducted in mice. However immunological
results in mice do not translate reliably to humans. There are significant differences
in immunology and cell biology between these two species that hamper translational
studies and vaccine trials. A theory that describes systematic differences in immune
response as a function of mass and phylogeny could have implications for the translation of results of experimental animal studies to increase impact on human health.
Our work is the first to systematically study how the response of the immune system and the pathogen varies from species to species. We separated the inter-species
differences into two categories: differences due to species body size and differences
due to phylogeny. The differences attributable to phylogeny would subsume differences in immune system cell types, cell biology, activation pathways in immune
system cells and types of normal cells susceptible to WNV infection.
Our models are a deliberate simplification of a very complex biological reality.
These models reveal broad-scale patterns in pathogenesis and immune response :
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1. Rates of WNV production decline with species body mass consistent with predictions from metabolic scaling theory [11, 12] (Fig. 7.3). These predictions
are modified by differences in phylogeny, e.g. most Passerine species have a
higher host competencies to infect mosquitoes.
2. Rates of adaptive antibody response do not vary systematically with species
body mass (Fig. 7.6).

We view our theory as a first step towards understanding inter-specific differences in the immune system. Such a theory could constitute a critical first step
in translating experimental studies in model organisms to humans. Our modeling
framework is adaptable and can incorporate new immunological findings as they become available. It can also be extended to investigate host immune responses in
other multi-host pathogens. We also suggest that experimental data from multiple
species, pooled and analyzed using hierarchical Bayesian models, can better inform
translational models and may lead to more accurate predictions of clinical trial end
outcomes like vaccine efficacy.

8.6

Implications for predicting spread of WNV

WNV infection progresses along multiple scales: infection within hosts is related
to dynamics of WNV spread between hosts by mosquito vectors. Coupling two
different processes over multiple scales, from individual cells to epidemic spread in
bird populations, is extremely challenging and could yield valuable insights. Our
model predicted host competency to infect mosquitoes can be coupled to models of
WNV spread between multiple species. Such an approach would help link withinhost WNV dynamics to dynamics between hosts and may help produce accurate
estimates of spread of WNV.
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8.7

Benefits of mathematical modeling

We have used many different mathematical models in our work: ordinary differential
equations and agent-based models; target-cell limited models and adaptive immune
response models; and multi-level and aggregated hierarchical models. These models
encapsulate different assumptions about biological mechanisms and allow us to test
the robustness of model predictions to these assumptions. Therefore it is striking
that our models produce similar predictions, e.g. the target-cell limited and adaptive
immune response models both predict that the rate of WNV production declines with
species mass (Chapter 7, Table 7.1).
Our models deliberately simplify the vast complexities of the immune system.
Nevertheless, these models reveal broad-scale patterns, e.g. the rate of adaptive
immune response mediated virus clearance does not vary systematically with species
mass (Chapter 7, Fig. 7.6). The tight coupling of our mathematical models to
experimental data produces insights that neither could have provided in isolation.

8.8

Caveats and limitations

The immune system has diverse cell types that mount different responses against
pathogens. We have investigated the effect of body size on the innate and adaptive
antibody (IgM) response against WNV. Although we have not investigated T-cell
responses in our models of WNV (since they appear much later in the course of
infection), we have simulated T-cell responses in influenza infection. Our modeling suggests that T-cell search for influenza infected cells in lung are facilitated by
chemokine signals in tissue. The speedup in search due to these signals is also higher
in larger animals. However we predict that time to traffic a critical number of T-cells
to infected tissue will scale with body size; the ODE model in Chapter 4 predicts
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that the number of activated T-cells that arrive at the site of infection in mice after
5 days post infection is 80,000 whereas in humans the number is predicted to be 190
(Chapter 4, Table 4.2). This is roughly consistent with experimental data suggesting that T-cell responses to HIV infection in macaques take around 1 to 2 weeks
[111, 112]. Adapting our T-cell recirculation model (Chapter 4) to make predictions
for T-cell response times in humans is an interesting avenue for future work.
Finally, in some cases our hierarchical Bayesian models produce parameter estimates that appear to be biologically unreasonable, e.g. the production rate of WNV
from infected cells (p) for some corvid species is predicted to be approximately 108
PFU day−1 , which is extremely high. This could be due to the fact that the initial
susceptible cell population (T0 in our models) is much higher in corvids, and may
suggest that other cell types are also available for infection. Further experimental
data on the susceptible cell population in corvid species may lead to more realistic
estimates of the production rate (since these two parameters are correlated in our
models).

8.9

Concluding remarks

Ultimately, this thesis represents a first step towards an empirical scaling theory of
the immune system. The mathematical framework presented here is an approach to
uncover systematic differences in disease progression and immune response in animals
that differ in body mass and phylogeny. There is potential for substantial impact on
human health since mice are the principal model organisms for most immunological
experiments. This could be extended to understand how drug and vaccine efficacy
differ between humans and model organisms like mice.
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The aggregated model has individuals of different species. The individuals are aggregated to form a tree of height 2. The model is shown graphically in Fig. 6.2 (Left
panel).
We denote the number of individuals by n and the number of experimental
measurements of virus concentration on the ith individual by mi . yij (tj ) represents the experimental measurements of logarithmic virus concentration in serum
for the ith individual at times tj (j = 1, 2, 3, ..., mi ). For notational convenience, let
µ = (log10 Vdose , log10 a, log10 M )T , θi = (log10 V0i , log10 ai , log10 Mi )T (for the proof of
concept model, Chapter 6), Θ = {θi , i = 1..n}, Y = {yij , i = 1..n, j = 1..mi } and
fij (θi , tj ) = log10 Vij (θi , tj ) where Vij (θi , tj ) denotes the numerical solution for V (t) in
Eq. (6.2) for the ith individual at time tj .
The Bayesian non-linear mixed effects aggregated model can be written as the
following three stages [113]:

1. Within-individual variation
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[yi |θi , σ 2 ] ∼ N ormal(fi (θi ), σ 2 )

(A.1)

2. Between-individual variation

[θi |µ, Σ] ∼ N ormal(µ, Σ)

(A.2)

3. Prior distributions

σ −2 ∼ Gamma(a, b), Σ−1 ∼ W ishart(Ω, ν), µ ∼ N ormal(η, Λ)

(A.3)

The Normal, Wishart and Gamma distributions are chosen to simplify calculations [113, 114].
The full conditional distributions for θi , σ −2 , µ and Σ−1 can be written as [113,
114]:

!
mi
−2 X


1
σ
2
[yij − fij (θi , tj )] − (θi − µ)T Σ−1 (θi − µ)
θi |σ −2 , µ, Σ, η, Θ, Y ∝ exp −
2 j=1
2
(A.4)





−2





σ |µ, Σ, Θ, Y ∼ Gamma a +

Pn

i=1

mi

2



µ|σ −2 , Σ, Θ, Y ∼ N ormal B −1 C, B −1
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Σ−1 |σ −2 , µ, Θ, Y ∼ W ishart D−1 , n + ν

(A.7)

P P i
2
−1
+ Λ−1 ,
where A = b−1 + 21 ni=1 m
j=1 [yij − fij (θi , tj )] , B = nΣ
P
P
C = Σ−1 ni=1 θi + Λ−1 η and D = Ω−1 + ni=1 (θi − µ) · (θi − µ)T .
The priors for the model were provided in the following manner - Ω was initialized
with the variance from the simulated data (all individuals aggregated),and the initial
guess for θ was randomly generated from the top level distribution, N (η, Λ) (same
for the multi-level model). The inference process produces separate estimates of
(Vdose ,a,M ) even though these estimates are correlated with each other.
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The multi-level hierarchical model has groups (species) with individuals in each
group. The groups are arranged hierarchically to form a tree of height 3. The
model is shown graphically in Fig. 6.3 (Left panel). Let there be m distinct species
indexed by k and the number of individuals in the kth group is represented by nk .
Let us represent the number of experimental measurements on the ith individual of
the kth species by mik . yijk (tj ) represents the experimental measurements of logarithmic virus concentration in serum for the ith individual belonging to the kth
species at times tj (j = 1, 2, 3, ..., mik ).
For notational convenience, we define the individual level distribution (ith individual belonging to the kth species) by θik = (log10 V0ik , log10 aik , log10 Mik )T (for
the proof of concept model, Chapter 6). We define the kth species level distribution by µk = (log10 Vdose,k , log10 ak , log10 Mk )T and the genus level distribution by
η = (log10 V0 , log10 a, log10 M )T .
Let Θ = {θik , i = 1..nk , k = 1..m}, Y = {yijk , i = 1..nk , j = 1..mik , k = 1..m}
and fijk (θik , tj ) = log10 Vijk (θik , tj ) where Vijk (θik , tj ) denotes the numerical solution
for V (t) in Eq. (6.2) for the ith individual (belonging to the kth species) at time tj .
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We write this Bayesian non-linear mixed effects multi-level model as the following
four stages:

1. Within-individual variation

[yik |θik , σk2 ] ∼ N ormal(fik (θik ), σk2 )

(B.1)

for the ith individual belonging to the kth species.
2. Between-individual variation

[θik |µk , Σk ] ∼ N ormal(µk , Σk )

(B.2)

3. Between species variation

σk−2 ∼ Gamma(a, b), Σ−1
k ∼ W ishart(Ω, ν), µk ∼ N ormal(η, Λ)

(B.3)

for the kth species. The Normal, Wishart and Gamma distributions are chosen
to simplify calculations.
4. Genus level prior distributions

η ∼ N ormal(x, y), Λ−1 ∼ W ishart(p, q)

(B.4)

Fig. 6.3 (right panel) represents these equations graphically in a plate diagram.
In a graphical model like Fig. 6.3 (right panel), for any node u, we can represent the remaining nodes by U−u and the full conditional distribution P (u, U−u ) is
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∝ P (u|parents[u]) ·

Q

w∈children[u]

P (w|parents[w]) [107]. The full conditional distri-

bution for u contains a prior component (from the parents of u) and a likelihood
component (from each child of u).
Following the principle above and simplifying, we derived the full conditional
−1
distributions for θik , σk−2 , µk , Σ−1
k , η and Λ :

mik


σ −2 X
[yijk − fijk (θik , tj )]2
θik |σk−2 , µk , Σk , η, Λ−1 , Θ, Y ∝ exp − k
2 j=1

(B.5)

1
− (θik − µk )T Σ−1
k (θik − µk )
2



σk−2 |µk , Σk , η, Λ−1 , Θ, Y





Pn

∼ Gamma a +

i=1

mik

2

, A−1
k


(B.6)





µk |σk−2 , Σk , η, Λ−1 , Θ, Y ∼ N ormal Bk−1 Ck , Bk−1

(B.7)
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k
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−1
η|σk−2 , µk , Σ−1
k , Λ , Θ, Y ∼ N ormal (z, Z)

(B.9)




Λ−1 |σk−2 , µk , Σ−1
k , η, Θ, Y ∼ W ishart (E, q + m)
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P k Pmik
2
−1
−1
where Ak = b−1 + 12 ni=1
j=1 [yijk − fijk (θik , tj )] , Bk = nk Σk + Λ , Ck =
Pnk
P k
−1
−1
−1
+ ni=1
(θik − µk ) · (θik − µk )T , Z = (U −1 + y −1 ) ,
Σ−1
k
i=1 θik + Λ η , Dk = Ω
P
T
z = Z (U −1 u + y −1 x) and E −1 = p−1 + m
k=1 (µk − η) · (µk − η) .
The priors for the model were provided in the following manner - the initial guess
for µ came from the generated data; Ω was initialized with the within group standard
deviation from generated data, and the initial guess for θ was randomly generated
from the top level distribution, N (η, Λ) (same for the aggregated model).
The code for both the aggregated and multi-level model implementations is available online [33].
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